STUDYID|DOMAIN|USUBJID|MISEQ|MIORRES|MIORRESU|MISTRESC|MISTRESN|MIRESCAT|VISITNUM|TAETORD|EPOCH|MIDTC|MIDY
Study ID|MI|d713606e-c808-49d6-878b-242fa5423a99|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-04|126
Study ID|MI|19276962-2753-41ca-93c0-b62eebf73043|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-08|137
Study ID|MI|fba486eb-0c9f-4093-83ec-7b3a3119e949|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-05-08|261
Study ID|MI|9b1d13e0-4298-471e-b0f4-e66662712e84|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-14|46
Study ID|MI|e7827662-389f-439b-bd52-bcc90880dae5|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-02-24|170
Study ID|MI|a1870039-6e2b-4170-8c6b-bd813a0f62f2|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-10|240
Study ID|MI|42b8617e-b2c0-4f9d-af9c-4c9618d9676b|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-24|37
Study ID|MI|ab5335fb-bc0d-460f-abe5-5d613b1b6afb|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-27|88
Study ID|MI|f975203f-2a45-4166-b937-afb03fb17d1e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-07-19|291
Study ID|MI|8faca3ae-52d5-4e2a-896d-9a5b86ea1a1a|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-08|297
Study ID|MI|b3a504cf-317b-429e-bb1b-39c4b1568a5f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-01|71
Study ID|MI|bc1b5635-3292-4053-8401-e257c00b5db2|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-09-24|25
Study ID|MI|2deec466-9b3f-4b48-ac64-56beeb018888|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-05|13
Study ID|MI|d5eff634-c07e-4933-9551-0f596a0a6aa3|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-30|260
Study ID|MI|b831f8dd-ec31-4fae-9e3d-1c64e6fcacb1|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-01-30|112
Study ID|MI|47665624-a6d0-4756-8af7-b3643cf402fc|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-05|187
Study ID|MI|80a01467-5aa8-45f7-919a-0e1e0046d252|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-21|131
Study ID|MI|5b2e3107-b84c-43dc-a5fc-43f02e7def1c|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-01-28|94
Study ID|MI|848bf545-6441-48fa-80cc-b97aba0d77c3|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-11-04|27
Study ID|MI|4c476a2e-71de-47b8-845d-73d5963ebf61|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-20|150
Study ID|MI|fd8e4cff-6799-40e2-84ee-a222b5d564ad|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-06-02|243
Study ID|MI|afc20884-6463-4dd3-a61c-c73566fde2d2|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-08-05|295
Study ID|MI|cafdfd6a-907b-4504-893d-b2353295e18c|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-20|243
Study ID|MI|6be30d43-dc8c-4406-b5b2-6461039ac501|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-16|122
Study ID|MI|2fa374c2-4d57-4de3-a86b-a3a374e6ab68|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-24|280
Study ID|MI|22adef60-8485-404f-99a6-70b3983d9d63|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-03|174
Study ID|MI|88be6386-17bc-4005-93f7-547e970c0162|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-09|276
Study ID|MI|3ae36993-0a7f-4299-9f2b-0af624d27fb4|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-14|25
Study ID|MI|67f55a16-dc5c-4ff7-b9e0-453bd287538e|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-29|204
Study ID|MI|b6a9a102-8ce6-48c6-ae0f-59c6a078f608|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-22|257
Study ID|MI|15a62d52-47e5-41a0-a12a-a88965957b79|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-20|238
Study ID|MI|eb675e48-769a-46e2-be7a-41aa1f53046a|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-02|177
Study ID|MI|2eafa16a-62cc-4f6c-b84c-e9fb97d7b423|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-11-28|30
Study ID|MI|f3614c5a-73d1-4268-b164-2eff0b860d10|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-05-26|283
Study ID|MI|4ee388d9-9a78-4a48-aee5-eee7065d8a24|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-12|254
Study ID|MI|2ac651d5-c732-44e4-8f9e-7fbe3078bced|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-31|57
Study ID|MI|19c4b5d7-3f8e-4d71-91a5-1c54ef1e6363|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-01-24|100
Study ID|MI|a6419434-b962-48b4-b026-86a708cdf45f|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-25|231
Study ID|MI|43b05d09-d9d8-4c7e-86ef-02a98a379637|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-12-07|55
Study ID|MI|617f2f04-58b4-4709-a5be-1b1fbd267629|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-27|107
Study ID|MI|8df00fbb-03af-45c1-8059-728b4e005ccc|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-22|103
Study ID|MI|a3dacbc1-5539-4c71-bb6d-5f76f67a6ac0|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-20|205
Study ID|MI|9c2bc89e-2ac0-412d-8a6b-f2e0b8dd2ca3|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-06|211
Study ID|MI|31f9ea80-527d-4eb4-ad98-6688f6347d39|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-23|244
Study ID|MI|5e138a4b-9752-4d7c-8e14-5287394d5e66|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-02|55
Study ID|MI|fff8406a-d54f-42c4-84df-3dc1c8a00753|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-01|298
Study ID|MI|22095a9b-6771-4df2-aa8f-1830ecffbbb2|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-20|232
Study ID|MI|626e1e91-37a9-4d83-999c-e073773869f5|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-09-16|26
Study ID|MI|0303e1ae-d354-4808-9f64-f02c8ac612b3|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-11-13|86
Study ID|MI|1281079e-bc3d-48c8-b66d-a5ac44b50c84|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-06-28|262
Study ID|MI|75a8da56-f2e9-4b0c-aa93-848992cff6f5|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-03|98
Study ID|MI|28957af8-b000-4d8f-8557-8580445d7f2f|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-21|57
Study ID|MI|61a0979d-56bb-41c0-9b78-6d99b39f776f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-05|70
Study ID|MI|6aaeef9d-a806-4440-8b57-98a81398d67d|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-11|43
Study ID|MI|65b0ce2c-b9c5-4c7f-a8aa-4bd6d555304b|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-06-15|253
Study ID|MI|d3acc9bf-719d-4f9f-9ee8-542bb9778058|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-22|211
Study ID|MI|9a35b233-5288-4376-9c63-5b86f8f6672d|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-06-15|233
Study ID|MI|e3d54bd1-a96e-4415-8c47-3476c9c7236b|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-05-25|213
Study ID|MI|abaea736-f6c5-4354-b783-5931177c9c7b|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-18|221
Study ID|MI|7d60d223-5bcf-4607-96a8-602c2de91f32|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-09-22|38
Study ID|MI|8a49d289-4d0d-45a6-aafd-79d3a1469c30|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-29|7
Study ID|MI|38fc7d5f-a83a-41e0-9cc2-00962bb1e016|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-10-30|68
Study ID|MI|8cb8b17b-558f-4b2f-b773-38119cbeed97|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-18|120
Study ID|MI|326bc136-7ef2-48a6-bf25-72481da70ba6|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-11-20|88
Study ID|MI|31859576-209e-409e-b331-46285e48e2b4|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-01|208
Study ID|MI|3432d463-0704-492c-aab8-f47f1eefdf0f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-04|181
Study ID|MI|e5cf09f7-8ebb-4b96-bb18-a6e0281d8e4f|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-07-30|293
Study ID|MI|4ec49792-4081-4e07-a478-009f715fe92f|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-01|159
Study ID|MI|395bc1a2-3aa9-4efa-b468-899beabd1001|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-04-25|250
Study ID|MI|1c47e5f6-4e35-409c-a891-ab52f28a0400|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-16|66
Study ID|MI|f102dfe2-cca3-4f55-a66b-858ca672663f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-16|59
Study ID|MI|a306acbd-a329-497f-9d5d-2787ea6700be|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-24|247
Study ID|MI|ee62f692-ae79-49c2-9495-a50194feba65|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-02|116
Study ID|MI|6848c047-d167-4a31-b2dc-0175ab0e9fb5|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-17|237
Study ID|MI|3634f8d0-a8c2-476a-a10f-be394a45de2f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-16|61
Study ID|MI|8406f0e0-f958-4cbf-b2f8-209bdc55cec5|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-03|203
Study ID|MI|a625107a-976d-4442-9bcd-06fb6630e271|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-15|49
Study ID|MI|4de184be-ccc0-4545-8c9b-138a71194fcc|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-22|114
Study ID|MI|2b3bad9f-1020-4540-8fb5-a28b1834a028|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-18|135
Study ID|MI|6f06fdd7-9b4c-475a-9a2f-fa63b6880f6b|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-21|191
Study ID|MI|34327bcd-ee05-4828-a302-a9edc20e9e42|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-02|116
Study ID|MI|528a5210-4439-40ce-a1e7-0597f7aa9350|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-23|61
Study ID|MI|a15a4209-7a42-4c07-b6fe-4a49bf5357c6|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-08|46
Study ID|MI|caf6881d-791f-42f0-afd7-885216350fd9|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-02|284
Study ID|MI|49d7b534-90c3-4790-8ed3-4bed04676ece|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-06-25|298
Study ID|MI|9d1a0f42-d590-4b1f-9368-22ee3a5e8403|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-18|206
Study ID|MI|38b834d2-d543-40b8-b25e-cec32309b253|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-10-07|10
Study ID|MI|80c7f221-8a14-44aa-b7aa-cf75bb6348b1|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-10-22|6
Study ID|MI|76f7cfaf-118f-4158-bcd1-99a21bb06da2|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-10|131
Study ID|MI|aeedb489-9c1e-480b-9baf-7e723060cd28|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-02-05|171
Study ID|MI|7d1d8119-224d-4ca8-94d9-d78a917ae454|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-20|95
Study ID|MI|f15ef6ad-be4b-4dca-8862-feb841db6887|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-09|184
Study ID|MI|967139c3-a1f7-4745-bc11-41e641e8bcfd|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-08-29|23
Study ID|MI|467a1f4e-ae0d-4f87-ba06-e60d270111d1|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-05-20|204
Study ID|MI|bec02309-a085-460f-be3d-cc290c5c3266|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-19|205
Study ID|MI|2151a119-37d1-4532-a75d-6e4945ad235c|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-06-01|290
Study ID|MI|76925097-8b5d-4db0-a753-80df265aa961|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-12|91
Study ID|MI|a15b3809-05c6-497d-baa3-575910ca6be0|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-07|184
Study ID|MI|be96372a-43f4-4186-ba38-af187089e655|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-09-03|26
Study ID|MI|c5e627be-f1e3-495b-81f6-13b445cdca13|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-11|245
Study ID|MI|99b8c1a3-deb5-432e-8589-679a52b0861e|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-12-20|106
Study ID|MI|2392bd8f-d606-464b-abf0-f66f06c8613a|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-10-30|43
Study ID|MI|84bda3cd-0134-47c0-b64f-97b25fc0fa04|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-25|159
Study ID|MI|3ed72845-5bef-446c-974d-2b7521c3eecf|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-01-07|118
Study ID|MI|b135e6c7-dd3e-47cc-9859-19398f2f6be0|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-09-26|17
Study ID|MI|4fdaf1de-23fd-4cfe-b96f-d0e8ed253a6b|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-10-12|8
Study ID|MI|614ca6ee-fba6-431f-8036-5c576b03c829|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-06-18|238
Study ID|MI|9ffc41b2-93bb-4a00-99e8-51f41ad10f1f|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-03-24|202
Study ID|MI|eb0c4506-7c3a-45c7-8a21-226a052ff830|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-22|69
Study ID|MI|0fb43761-7a6d-436f-8bcf-cf2d3ace4f9d|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-01|172
Study ID|MI|9e31425e-d439-40d6-a518-c76b9d0c221b|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-12|78
Study ID|MI|0b28391a-5735-42c9-8c0f-fe2f499180ad|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-30|79
Study ID|MI|d4bdfcb0-f9b0-40b4-8a2b-ee14ecc4a788|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-20|277
Study ID|MI|072bccd8-4efe-4b27-b304-52dad87c879d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-04|221
Study ID|MI|1d852bb3-1772-4eb1-85a6-79cbb41f2f29|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-01|168
Study ID|MI|a7a714e9-49e2-4e73-ad90-0fecf0d35cf5|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-23|189
Study ID|MI|948c63c5-3146-42c3-b999-794f4f7eb5ac|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-08|87
Study ID|MI|b5eaeff7-2cda-4196-a352-bb42cf321606|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-23|201
Study ID|MI|41c087e5-1dfb-4285-96a3-fd59076e5717|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-20|119
Study ID|MI|1ff7c459-01b3-4598-838c-7f3f9eacc752|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-01-08|140
Study ID|MI|f30f326c-bba6-4e50-98c4-2654c1cbea4d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-05|197
Study ID|MI|88f49917-6cc4-4bfc-bbcc-d0ef408649f2|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-09|67
Study ID|MI|38d60c2e-c043-47cf-9ef7-5e1346d65d5d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-03|111
Study ID|MI|5dc6b4b8-9cce-42ce-8186-5d9515e52929|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-02|101
Study ID|MI|a756e1c5-dd35-47cf-b3e2-610b6595dc15|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-21|30
Study ID|MI|4f75fe33-11e7-4c44-8a39-6391188b1db5|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-01|189
Study ID|MI|d1bd1be2-7172-44b3-b1d5-32a3d377b4d6|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-06-27|297
Study ID|MI|053425cd-706f-4d2e-847c-5a779ae9b2ab|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-25|154
Study ID|MI|4bd332b3-6cd8-4e28-94ef-0b1a0be0a002|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-23|132
Study ID|MI|e01de567-61df-4da1-8dcd-7190d1b9d889|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-02-14|111
Study ID|MI|7569cb98-81bf-4117-b076-8e27f6a12eee|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-18|139
Study ID|MI|ffc9571a-170d-44d9-be33-4e602e45fb1f|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-05|165
Study ID|MI|1a307872-c540-43e0-b6cf-6c7abd48bd34|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-07-28|290
Study ID|MI|ae0d4887-73ee-47ff-98df-69e53708973a|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-06-01|260
Study ID|MI|a9d0cb3a-b2bf-442c-a297-b01e8e701c6b|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-01|18
Study ID|MI|5988e1e7-9658-4677-be9d-c61a0cb2cc95|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-27|213
Study ID|MI|fc101382-4916-4ee4-bf00-6398e8aece08|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-03|52
Study ID|MI|93dc1418-6279-4db0-b55b-a26645a9b30c|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-14|39
Study ID|MI|166f2758-b6c5-4439-9201-22007ca181c7|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-23|166
Study ID|MI|dfe799ef-40f8-4293-ae08-fefc54ae3bd1|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-11|121
Study ID|MI|a385105b-f0f8-4f28-9f0d-83590bdbb515|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-11|128
Study ID|MI|808520d3-3b76-49bc-b3af-bc2fe89292ce|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-11-25|92
Study ID|MI|7a0b128e-56a8-4dc2-9fff-5da61f895cc7|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-31|164
Study ID|MI|958d143a-5381-49c5-8bd4-57e1369c3c83|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-03-27|188
Study ID|MI|1b08fa0e-c785-4e2b-ade6-764dc0199b46|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-10-03|30
Study ID|MI|9e430cf4-27f1-4fd8-abbb-1971b7f6698b|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-06-15|257
Study ID|MI|fc84f14d-27bf-4f2e-beb1-af50ddf975b8|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-01-23|95
Study ID|MI|e2242eef-d92e-40e2-a481-3da17eef3d9f|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-21|60
Study ID|MI|fb8e4e6b-79e5-4a38-bb3b-8b9dea8d70b0|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-10-22|58
Study ID|MI|c416dd33-f0c5-4097-8be0-a8baef1f41ab|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-09-15|14
Study ID|MI|33606058-1c76-4b31-bb71-b25bc019dacc|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-07-05|250
Study ID|MI|b3117024-d79c-4ba6-bc57-cd5e32352abb|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-16|49
Study ID|MI|5f681c2a-5efd-4774-bfb8-d031fbdd917d|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-19|86
Study ID|MI|a9e04609-9af3-4587-8ac0-a8d62854939a|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-18|202
Study ID|MI|0913ad12-1f57-4c53-953c-53b2c77d6916|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-13|215
Study ID|MI|5621f735-4c04-4865-ae76-417f931fc416|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-07-20|281
Study ID|MI|d2815dac-314a-4b51-a2a8-7c34342d8762|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-29|163
Study ID|MI|1e4a58b7-6c40-49c2-8366-ab18bde326ba|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-23|215
Study ID|MI|6142ec67-5b3f-4b25-ab15-4b89681287aa|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-25|93
Study ID|MI|f3d1a010-45e4-4136-985b-2c267cc61bc0|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-05-09|266
Study ID|MI|02731faf-c909-4245-bde8-9ed89623636c|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-04-05|203
Study ID|MI|f41c7623-dc71-40b6-af05-cb27bcc5bc0d|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-15|145
Study ID|MI|3ca6f491-6adb-461e-8c77-6964298881b8|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-14|224
Study ID|MI|348c5733-3f80-4958-aed9-788cae022359|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-28|277
Study ID|MI|25afbbe4-4844-47b1-a1f2-719a1d539a7e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-03-01|193
Study ID|MI|ebdeac60-a9e0-40b5-a156-2e65c3d34ece|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-11-11|25
Study ID|MI|0a056ab2-3769-4bb4-ab9f-581f1f302e5e|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-12-31|122
Study ID|MI|0dc6f54f-28d3-4e98-9202-ecde1228feba|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-08|82
Study ID|MI|a918255d-29fb-4e33-b0b7-df6fc4790307|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-11-19|52
Study ID|MI|cca42372-642c-4914-89be-334f5e371202|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-13|126
Study ID|MI|ef11d251-ad64-4ee8-8924-97229080b97f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-15|163
Study ID|MI|c81be2c6-6a71-42ed-821c-2539d90f9da6|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-20|67
Study ID|MI|195e00af-25ec-43b2-98a0-b7dbb0918556|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-02|134
Study ID|MI|166f2644-d223-48de-a053-7a7931229ea9|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-06-26|276
Study ID|MI|50f00565-e065-4bb5-906f-43b4994f05d9|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-01-04|135
Study ID|MI|25be6337-0010-4c3f-a40d-73f1970be014|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-07|171
Study ID|MI|51665699-7b2e-4584-ba77-1495e49154c8|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-23|112
Study ID|MI|677139a9-de5a-46e8-9b01-78b89bb5721c|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-12|164
Study ID|MI|875a63c3-b499-4a5a-8b56-ca6d10bf9c26|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-10-08|60
Study ID|MI|07f84376-6ab5-43a9-8ee5-51f2f8046eb2|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-22|275
Study ID|MI|b179358d-b542-479f-8a24-8cd656f8b29c|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-14|168
Study ID|MI|f2b14285-7731-41ba-803d-a13079c8d7e2|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-06-07|251
Study ID|MI|01dab730-8fa8-48b8-9db4-549d17fe9364|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-14|192
Study ID|MI|91824814-dbc7-42f2-933a-843c745307f0|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-10|209
Study ID|MI|0a8847a0-ad08-43f0-8f7c-09194197ded3|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-30|167
Study ID|MI|3ef841f6-b1d8-41c0-a708-ed1a2866d92b|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-13|74
Study ID|MI|ec732f35-e389-42ea-b5c1-5795312935ac|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-03|215
Study ID|MI|ae055ad4-6e9a-47f9-8914-6bab08f739fc|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-10-21|45
Study ID|MI|7d95af47-fe69-49d0-b3c2-0b4b011bdf97|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-06-29|299
Study ID|MI|ba667dad-f75a-4736-b891-0bf204438374|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-30|261
Study ID|MI|86bf2d3a-e791-4eec-8ef8-6aa975a23d46|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-23|186
Study ID|MI|e223e6f1-4f84-4ae8-9621-67d13737279a|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-08|108
Study ID|MI|6b71d31d-4466-4699-a4d8-38998456913a|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-28|72
Study ID|MI|6a8b54cc-5569-4c3a-8f25-d0a357c23c1b|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-10|200
Study ID|MI|d7453b4b-c700-4116-88e0-5ec07255fcc1|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-06-13|286
Study ID|MI|97846c4a-bc01-4a2b-9d5a-15f44d085c04|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-05|191
Study ID|MI|6ac67159-7286-4911-9ffa-136fbe29e4f3|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-14|178
Study ID|MI|71bb085e-762e-4807-bf68-38c734740c69|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-07|199
Study ID|MI|c44e84f0-4142-417a-b150-0f869ba0b626|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-17|147
Study ID|MI|beafde56-2984-4fbf-ae59-57666400ec13|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-01-25|168
Study ID|MI|1bd533cc-d6ad-4b46-b65f-22521af557c5|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-16|82
Study ID|MI|ea38ac51-e63c-4105-a611-7f82e602e40d|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-06-13|295
Study ID|MI|d0ffcc8c-51e8-4e39-bff1-70ee52985b9e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-15|238
Study ID|MI|1d54d4f1-bde4-4686-96bf-d1d78ab25874|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-29|143
Study ID|MI|d0902968-a6cd-4b8d-bcf8-4da11b088679|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-12|155
Study ID|MI|dc30ce6d-7caf-4baa-a7ef-368c1213ba44|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-05-04|231
Study ID|MI|72574893-e8f5-44d2-8e9b-ef6b0d1f5f7b|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-21|36
Study ID|MI|e246564a-8c28-4bba-b70d-12cc38919ed9|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-06-02|260
Study ID|MI|c04a3991-7665-487f-916f-f695b3a91afa|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-09-06|26
Study ID|MI|808e1ec0-c263-4209-a16c-28d78a445acd|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-21|171
Study ID|MI|9725ad20-8ca3-48e7-824e-7dba1da8abdd|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-08-23|9
Study ID|MI|12fe384b-bcd1-4b63-855a-0c5e220b6caa|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-26|156
Study ID|MI|42351b79-f2f3-4c6f-9d70-2fab11eca35a|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-12-03|55
Study ID|MI|1850f6e3-d8dd-48a2-a4c1-7676bb1fafd5|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-12|184
Study ID|MI|cdf46a68-d9ca-4645-a48a-93ffb1cab1b7|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-01|118
Study ID|MI|8ca35852-d560-4920-a83c-0ce950d886ec|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-02|141
Study ID|MI|b1c9bc78-2257-44c2-8b8b-6426cf6d3e7c|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-09|244
Study ID|MI|3f85e60b-02d4-49f7-b18e-165a3111bea7|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-07|96
Study ID|MI|cde9f3d9-ddee-4509-8eb7-a564be85aaff|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-12-02|43
Study ID|MI|3107c700-6a04-4e10-ad7c-cd8a0311386d|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-06-23|298
Study ID|MI|ff8ce288-b923-44e6-ae07-5dac29048b6d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-07-31|287
Study ID|MI|83270fc0-01ac-4d5a-807d-bb4a7bde1c7f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-06|215
Study ID|MI|764b8b95-3ff5-4ed7-992b-0eddc8f2f042|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-01-18|111
Study ID|MI|9c54af9a-3b79-4bc6-807e-71b15c34adf8|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-26|107
Study ID|MI|a8c7879f-9b99-4eef-8bae-5f2045165742|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-20|144
Study ID|MI|3335ac20-54bb-4eab-a1a3-bad43caa109b|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-11|214
Study ID|MI|d756c97e-423f-4dd4-b738-c969a1b08461|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-11-19|96
Study ID|MI|94d170c2-fc3e-45f0-869b-471e4f0c613a|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-16|288
Study ID|MI|9a166b73-8cb2-43fa-aeab-7d2ef06fe7e7|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-19|240
Study ID|MI|a04b7049-49aa-4c99-8705-4962cad4040a|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-02-16|182
Study ID|MI|3cf1a0ae-c84b-47be-a432-b5e4293bfc26|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-07-12|276
Study ID|MI|9819ea3f-0f7d-4e01-8c85-c9aa2db89060|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-06|17
Study ID|MI|31705791-d8b5-4b87-9a86-b3e24475463d|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-06-03|273
Study ID|MI|aafbdfe9-c0bf-4729-98b5-6d4a48cd0100|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-02-15|111
Study ID|MI|52373cda-1ccf-427a-baea-1fa13a0a431c|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-14|228
Study ID|MI|609f31d1-1a82-4f98-acb3-4d6674d56ada|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-23|214
Study ID|MI|8fcf9829-8812-434a-a31d-123cbbacbdf5|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-01-15|91
Study ID|MI|a259b1eb-481b-4ef5-8509-c110c0aec4f9|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-12-06|72
Study ID|MI|1cf3ce30-295f-4ff8-8556-2fe8cb8b0bc7|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-01|206
Study ID|MI|28e37863-8010-4475-a326-ca687a0b1c77|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-19|48
Study ID|MI|e59eba09-9366-4808-b6df-5d6974f6ff34|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-26|197
Study ID|MI|61d5efed-8673-4e45-8d71-455182e69f36|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-10|169
Study ID|MI|93cb4676-6d85-47d2-8abe-9e2894c1988e|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-07-04|290
Study ID|MI|0230d010-e393-4a25-9d74-1f04f04a62f4|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-26|181
Study ID|MI|98dc4659-5b52-461c-b74a-a9475a5a5d6a|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-08-24|4
Study ID|MI|36277ed8-38e6-4056-b51d-928ec80926e7|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-09-14|27
Study ID|MI|0d0321a6-ccd7-468b-963d-27c9faef7f5e|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-10-01|12
Study ID|MI|73c43d89-0f5f-41fc-8b2f-123abce98d5f|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-06|135
Study ID|MI|6f8b89c1-09b9-45a1-ad04-191a1d7b31d9|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-29|84
Study ID|MI|380a12da-1c9d-436f-920e-574406d171fe|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-10|214
Study ID|MI|a9d6d2e3-38a5-47ca-bbb9-c0e41e8432b7|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-25|265
Study ID|MI|c9483c30-fed5-45b9-85cf-299559cd97b7|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-03|234
Study ID|MI|70b6a549-03e7-415f-9af2-ab9183c1a78f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-03|225
Study ID|MI|f3c55f64-987f-4ab7-bb31-821dc6fc0d96|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-07-01|259
Study ID|MI|ecc23866-885e-403c-bf01-5cce2a7c010f|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-07|167
Study ID|MI|665c979c-d076-44e0-9f76-4869bc22b09e|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-04|139
Study ID|MI|1533f51f-0564-49ad-bf8c-472538fa03a4|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-12|24
Study ID|MI|d15001d4-14c3-440c-bac4-6fb4414fb410|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-28|11
Study ID|MI|9b8601b3-75d2-47ad-8256-b10ee9e99123|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-01-19|100
Study ID|MI|dc90d8f8-a9d3-4869-8b00-9a75bcc1e302|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-27|247
Study ID|MI|1f338414-9f49-4dec-bcc2-a20311ab653a|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-18|148
Study ID|MI|12728dc0-3f6a-4d2c-b396-b6bcdb2927d1|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-23|58
Study ID|MI|24a85a44-fd7a-45d8-bcb5-cf65e095b4e5|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-12-24|71
Study ID|MI|7dcec4d6-6b65-4340-8f44-54730c0671f4|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-02-05|142
Study ID|MI|129a67f2-3c33-4322-9257-08f9b1b2adb5|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-09|244
Study ID|MI|24cab1dd-d866-4de2-ab08-4d9242db328a|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-12|246
Study ID|MI|bbbc30c5-fb5f-4424-90ce-32f90a80ea4a|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-05|56
Study ID|MI|1ca6d30a-3042-4e3b-85bf-d07738068c8d|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-15|136
Study ID|MI|0ab2aea5-1905-4e6d-abfd-c1cfd6c3c6e0|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-19|173
Study ID|MI|d5e867a2-5911-4645-bbd0-df9f0d79d8bc|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-29|70
Study ID|MI|7f7be32a-b13e-4866-a1c2-00da92af3f92|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-06|50
Study ID|MI|8824d842-e09b-4dc2-96bd-080b228c8a6c|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-20|198
Study ID|MI|6f6d16b9-f088-4b48-a9d7-5620b38212f4|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-19|158
Study ID|MI|f5e4e708-55f2-4281-a8ed-b42ef27f6671|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-10-23|7
Study ID|MI|2bc210d1-2103-45a9-912d-c3b940211dec|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-23|55
Study ID|MI|0f8419dd-1497-4496-8cd5-77cc5af2a2bb|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-09-30|27
Study ID|MI|94ba310d-113e-45d2-a7f2-3bb52a0f83e6|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-26|179
Study ID|MI|cacf3cf3-3c48-423c-9b15-1563573b9e00|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-23|31
Study ID|MI|98603ea2-3f67-4f4b-87f5-5b5705b3538d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-10|191
Study ID|MI|bd3d322d-1da9-41ad-865e-f25599f98687|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-04|137
Study ID|MI|eafb6349-037c-413d-a4d1-13d105700f04|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-01-27|149
Study ID|MI|040ec88f-f136-4e8c-ab55-70d2f1d87728|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-29|265
Study ID|MI|3d2eaf49-98cb-450e-a0f4-8e188a3e9743|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-07-02|284
Study ID|MI|9222e497-21a6-488c-b8a0-11f0fb12eaf3|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-14|234
Study ID|MI|573ab644-6f30-4f50-a499-22968a99d3db|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-05-05|254
Study ID|MI|9f896e27-284d-437c-9e61-a7b9b1e1dcc9|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-15|181
Study ID|MI|ac59aed4-fda2-4cf1-bb80-8075cb35b853|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-26|236
Study ID|MI|09a644bd-a8cd-45a1-bde7-2711c8f7be76|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-10-19|54
Study ID|MI|fb28d99b-b4af-4d3e-9b66-25f3a7ba0b60|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-29|44
Study ID|MI|953c03ac-2ac5-4419-80d4-8dfaa9d764ed|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-11|280
Study ID|MI|35dc4735-9b9c-4dc3-bbd6-c500edecd2e2|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-05|82
Study ID|MI|68a9c486-1ea0-4faf-b116-0d99639f5ac0|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-18|183
Study ID|MI|0fef3c1c-47d7-420c-9130-7e4daf02e4a5|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-10-30|22
Study ID|MI|cb2a7cd4-3814-458f-8d9f-1d9d501a5493|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-20|255
Study ID|MI|fe5681d0-ae8f-4138-a471-b3987b3ecef2|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-03|15
Study ID|MI|78099927-98e6-481e-975c-6db28590527d|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-25|288
Study ID|MI|63867bf1-8945-43c8-9889-45315844a1ba|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-15|45
Study ID|MI|746358fc-dc62-47e8-840d-c41f56096bf1|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-09-26|7
Study ID|MI|bba7936a-2e13-460c-b5d6-4e05d61ff34e|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-08|149
Study ID|MI|4913facb-a897-4a54-bf00-03e8de26dea9|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-21|254
Study ID|MI|b9fc69bf-5074-43b3-bb5b-ef5a9274bb9f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-05|136
Study ID|MI|18d9c429-a7fa-484d-8ad1-aff9c485ccd5|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-08|227
Study ID|MI|f96f2f97-2dde-4b49-92d6-e2318b5b8dd6|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-02|149
Study ID|MI|9aa605b0-f301-4a30-a77f-b8ea80c5404e|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-07-30|276
Study ID|MI|7d3a3c79-4678-477a-a2e4-006e877825e9|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-12|148
Study ID|MI|c1890918-1c35-4e9c-91c4-3eda13542117|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-10-02|11
Study ID|MI|0c945d4a-80ce-4068-861c-44af5f738490|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-01|161
Study ID|MI|e79af959-1fd9-4849-9443-43591b71e62a|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-01-28|104
Study ID|MI|4d43d548-e243-4110-952f-14ada154970c|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-01-31|119
Study ID|MI|30320185-e97c-4242-ae4d-cb24611b7750|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-16|237
Study ID|MI|5d0127ff-c151-45eb-b3b7-926bfe449838|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-05-29|259
Study ID|MI|25c04c0b-c392-474c-a3d5-82711041ca1e|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-10-29|2
Study ID|MI|bcceaae7-1012-4528-be14-489633f52157|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-10|137
Study ID|MI|8c6ca613-79a4-447f-89e4-ea0774da639c|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-11-18|80
Study ID|MI|cec457ac-fa41-4b67-9fd8-f0754d6c23a1|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-05-31|278
Study ID|MI|b162843c-5086-4bd5-ae65-072fb1dc8140|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-07|251
Study ID|MI|eb87675c-9d36-455b-b08d-3ff38da1bdcf|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-01-16|83
Study ID|MI|db09cf52-bd36-44dd-ae61-446ebfe27d96|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-30|229
Study ID|MI|81ac7f9e-c4d4-46e2-8539-0ad8ad46df96|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-02-22|167
Study ID|MI|c7bcaf1a-6382-4247-ba8f-1b2eab6a072f|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-18|149
Study ID|MI|05997ac8-3c85-45ab-aae5-2fa752d4dcbb|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-19|102
Study ID|MI|615e5774-576d-4bf2-bf4a-d037187fc9dc|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-25|92
Study ID|MI|4b45ad63-686b-48d9-a170-e68e3986e094|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-28|203
Study ID|MI|de28132b-7820-42e2-b6ed-73122f687503|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-06-15|251
Study ID|MI|ddf32ab2-063e-4e0c-a39b-1b62fafcd9c0|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-29|290
Study ID|MI|1012002b-2a83-4649-97a1-7abae8449749|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-14|145
Study ID|MI|4f2dee02-6b3f-488e-aab1-9ae321997823|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-25|269
Study ID|MI|b30d18a1-37bc-4b36-800a-dc7fef2b9121|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-09-16|9
Study ID|MI|d1e3fd18-c1ac-471c-95fd-210c5f45c90f|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-11-23|71
Study ID|MI|460242c7-6626-4d89-95d7-122a274cacbc|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-01|213
Study ID|MI|80564fe6-89a7-48ca-970c-8fd6cfb2faa9|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-11|54
Study ID|MI|a0290e05-7c42-4d9b-a5eb-c8ad65bcfd2b|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-06|63
Study ID|MI|5a5ac5e2-564e-4cde-b25b-bf9a69399310|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-14|172
Study ID|MI|bf7ab21f-d573-471a-9b64-2c0b952994dd|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-07-09|289
Study ID|MI|f7cfadf0-f78d-4548-ad04-8d37e6d031f1|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-02-22|166
Study ID|MI|e2a9612c-3b14-4b8c-ac88-39ac9de31c2f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-17|113
Study ID|MI|ef8e1969-22b2-4191-bb95-209af30b5096|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-08|140
Study ID|MI|aaab833d-2546-4606-a806-4fbed4c00eeb|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-07-29|281
Study ID|MI|ceebe624-3386-406a-a055-e7d4952cd37e|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-18|173
Study ID|MI|131a7b87-c5fb-4176-841a-b4d1af976105|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-28|187
Study ID|MI|1ce2e510-e54a-46a7-8bed-d9c786d428de|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-27|142
Study ID|MI|c7c28c4a-e559-497a-8181-fe015050b12f|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-09|127
Study ID|MI|79564b04-8e29-4939-8810-6c637d1d4504|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-15|129
Study ID|MI|f9cf9898-ea99-474b-a173-15b8e0068065|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-07|190
Study ID|MI|c7990059-5e9d-41da-8832-f19ebf5ce11a|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-25|46
Study ID|MI|b1f6503d-502b-47b3-9266-ba6cfa45c138|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-10|153
Study ID|MI|1f200d28-91a8-43dd-acdc-76276cc05e00|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-06-06|259
Study ID|MI|9ed5969e-2bab-4e80-96e2-5200f770ba03|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-07-09|280
Study ID|MI|0c4ce5af-6958-46b5-9475-1b3a4fc0d33f|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-05-25|281
Study ID|MI|69c9c9dd-3ab0-4a43-94c8-9c40b580b4f2|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-03|160
Study ID|MI|54911800-8507-499a-a7a0-7f2d2fb091d3|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-19|64
Study ID|MI|62d81c3b-7e47-4ca1-9b1b-5ae8ba53e4d5|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-01-22|101
Study ID|MI|5c3a10c5-ff6d-4848-8fba-89ed56deebcd|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-06|198
Study ID|MI|100085d7-f49a-468d-a92d-0304e65f71b6|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-24|64
Study ID|MI|9cbde452-5eb2-4af6-b986-456a7d96594a|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-12-25|127
Study ID|MI|8e171a3f-46df-4df0-9a45-ef1577574095|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-30|288
Study ID|MI|099b7ac3-d3ae-4370-a687-a9829c374dd3|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-01-17|87
Study ID|MI|7d023693-f052-4b93-8706-1cfc6754f05b|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-16|172
Study ID|MI|975abcca-91ce-4b91-b607-3967668b0432|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-05-08|203
Study ID|MI|3831851f-30ba-47d0-8ce2-565af7ed3055|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-12|116
Study ID|MI|e691e72d-cc4a-4256-913c-9889f5282c2b|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-16|172
Study ID|MI|eff0d0b0-90a4-49be-8963-0e1e14b65c99|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-03|179
Study ID|MI|923bf4b4-2489-4fb8-bde3-b5747b98a128|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-13|110
Study ID|MI|754a5564-4735-449b-b57c-8909371e4ea1|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-22|5
Study ID|MI|a2f1f1f7-ee92-4e60-97a7-6b506252b2dd|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-21|146
Study ID|MI|12e2e175-84e0-48bf-8a02-1cbdb8b7a646|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-24|184
Study ID|MI|1f46fe9b-33e4-4555-9195-7acaf5d149be|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-10-28|57
Study ID|MI|caf416eb-7ca0-45be-bbff-f39131db02ef|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-04|226
Study ID|MI|1d94fa8d-4e72-4d3b-8d50-b5a276fdbdf9|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-13|107
Study ID|MI|00ae1afd-197f-472e-b400-614a5c0859e8|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-29|244
Study ID|MI|ccd0534d-432b-4bbf-82d2-075fad3a74b7|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-01|147
Study ID|MI|0d66f896-f5ed-4f9d-8568-47d4708f5348|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-07|231
Study ID|MI|2f83788c-5f95-47c0-91aa-a8577b6864ae|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-01-06|101
Study ID|MI|67ea82d1-7c31-47dd-a86d-735cb8959645|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-06-28|247
Study ID|MI|a120fa16-f4c5-44cc-b4b7-d48d3e6ea808|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-10-31|46
Study ID|MI|da347bd5-04a6-4702-9bdf-d423296bd37a|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-19|60
Study ID|MI|c6935776-c0dc-45a8-b6ef-4f0b0df78049|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-07|141
Study ID|MI|e078c95e-c244-42b3-a2df-de4a04c44045|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-12-06|71
Study ID|MI|9741b905-8565-460d-8dca-06ccf0ce4e46|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-19|255
Study ID|MI|a1d554e2-e153-4703-ac09-a261b054d818|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-03-31|212
Study ID|MI|2bfaca0e-7432-4006-82f9-df89cd638dec|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-06-01|231
Study ID|MI|73e211f4-249d-4736-b234-bfbc04721709|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-16|271
Study ID|MI|8d0d1112-a65d-4ad9-bce5-7f5c11bec70d|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-15|126
Study ID|MI|50303234-a96f-4a05-a979-d5f199e465c6|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-16|122
Study ID|MI|1ed4eb06-a61b-4ee8-a2ee-3e8ddcc09a16|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-02-08|167
Study ID|MI|4386650d-d299-4d8d-a657-58c847fb8c00|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-22|127
Study ID|MI|363b577d-5a9b-4cd5-a353-5ac7547e0b69|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-10-09|32
Study ID|MI|0dae606b-1594-45a8-a22b-f01abc193c6f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-06-05|242
Study ID|MI|29b7909c-0caf-4a3d-98dd-f1dc96294bcf|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-12|166
Study ID|MI|caa5f408-9834-4b2e-b07a-acc62f7e6606|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-07-13|258
Study ID|MI|04820ebc-945e-4625-a6e3-b40c32e374f8|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-01|59
Study ID|MI|cf5c476b-1fa3-443b-b692-e1749ec1a311|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-24|169
Study ID|MI|c472e3b9-65a2-4eff-a2f8-2795a8dcb69a|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-10-09|4
Study ID|MI|318c96b9-51b5-46c7-ac4d-6bebe6060498|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-05-25|222
Study ID|MI|7741ac05-c3df-49b6-bce4-593b34a9dd72|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-15|74
Study ID|MI|17381173-41bd-4620-83dc-ab51611d807e|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-12-31|109
Study ID|MI|99233170-3f1d-4cea-acca-6a9df5e53fb9|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-01-02|139
Study ID|MI|e25f381b-35ad-4e0e-b68f-5064f975797c|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-12-12|86
Study ID|MI|c01e42ba-3c20-4dc8-8275-973b23c7d24e|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-03|168
Study ID|MI|1e88658b-be76-4197-a4ba-5e9e6ecf9510|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-22|84
Study ID|MI|8f7bdef5-9a74-42d8-b249-33b99356ce97|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-04|38
Study ID|MI|ff8bdf28-42ca-4c5b-ad57-231fb9e9eab8|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-07-17|295
Study ID|MI|2b7f19fd-2b74-43af-96e6-d3277f9bfb16|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-10-01|29
Study ID|MI|e8c495d0-b9c2-48a0-9846-f0cd24df8675|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-06-10|251
Study ID|MI|102375bf-0d0d-4b6d-ad07-e82886eebd33|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-21|256
Study ID|MI|2cbee9a8-b1ff-45d7-95e7-444c53088ec6|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-01-31|160
Study ID|MI|d8fa5a4c-28f1-48ba-a463-83a0f2149944|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-24|51
Study ID|MI|7a8957a1-9945-4a8b-84be-4f5c7b3f2f2d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-26|74
Study ID|MI|5df59b18-8e89-4f71-aa42-e67131bcca74|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-21|89
Study ID|MI|33bc825d-2eef-4f45-92ad-9fa4a1041abc|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-30|138
Study ID|MI|79aa6da6-c48b-465d-a8e3-8a70cc7fe0a0|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-05-09|255
Study ID|MI|25a0f0de-927e-42b6-8806-8694ba57fdbe|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-19|224
Study ID|MI|6a1315aa-839b-4b9e-b531-04697602c150|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-11|206
Study ID|MI|0424f6df-1e7e-4656-8d05-94b93de045f0|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-05|219
Study ID|MI|edc797eb-dcac-465a-90b3-7200364e4115|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-09-14|6
Study ID|MI|d3c66bad-a6a4-4ab2-8ab9-16c6062f4e37|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-11-12|54
Study ID|MI|ed11b631-0d04-44fe-8581-179d81848148|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-05-12|214
Study ID|MI|5f46adb9-5194-4421-ba70-2f276b9e82c5|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-03|232
Study ID|MI|02ce4273-a033-40ac-b8a0-aae023732aa9|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-09-07|6
Study ID|MI|2725ff54-6e0c-4857-8749-13096a80eedb|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-23|188
Study ID|MI|0b84fe7d-fea2-4025-a6e5-30d14d9669c2|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-21|78
Study ID|MI|8d66f913-08d2-4c0e-b662-91e2ce0a7d1e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-07-04|270
Study ID|MI|2baf42c1-e2c2-46e7-b559-a4f27dde2a62|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-09|213
Study ID|MI|3b938a08-d41a-4b13-8fca-02fdcea7459f|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-21|219
Study ID|MI|24c2989c-3b77-401f-a162-b1dcfb9ba02a|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-19|101
Study ID|MI|5b5dc815-e7bd-40d1-bf51-8c1f383eaac3|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-05-30|223
Study ID|MI|3a612fb3-b197-437b-b1e2-2205114ebbe9|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-18|7
Study ID|MI|0cfe074e-2d3d-4985-8187-30ccbf1327f7|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-03-17|179
Study ID|MI|fd90b54e-45f0-4c57-8be7-ea03b4ba72bd|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-17|223
Study ID|MI|d2ee9a68-accc-410b-afcd-465f50b2549e|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-21|170
Study ID|MI|6115f166-0c52-4e50-bcd7-5077eb324052|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-09-02|3
Study ID|MI|33cc84d6-d563-4122-9e12-2f5f4d108d3d|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-07-30|278
Study ID|MI|a8e4d91e-ec8e-43b7-b6ae-6d6531a5d183|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-23|153
Study ID|MI|39005f68-0383-4062-a43a-73af8fc6ed79|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-04|243
Study ID|MI|07ad428b-af9a-4329-9020-edfc3510efb7|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-11|173
Study ID|MI|6afbc143-c718-434e-b2c9-90fb94d15e5f|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-30|178
Study ID|MI|9a2bf45c-ff6b-42d1-b37b-1d9227a57adb|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-02-16|132
Study ID|MI|fc67788f-0782-4e37-ab27-87ed60178271|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-02-18|151
Study ID|MI|934efb57-d68c-40b6-9677-2bf5af0f5afe|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-05-18|214
Study ID|MI|3fb1940f-49e7-4d22-89c2-49fa8ba12b8e|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-24|212
Study ID|MI|434b2cb0-e767-4f5d-97fb-c71c8624cb48|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-01-30|175
Study ID|MI|bac51837-53f4-4785-98bd-a7fdeb04e309|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-10-08|32
Study ID|MI|7978ecc6-c84e-4c79-bcec-9034523ed0ec|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-20|90
Study ID|MI|41baa737-5c54-4341-97a5-39eba1110af5|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-28|201
Study ID|MI|1639ffae-9892-4db3-bcf1-8ec410d02017|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-03-25|171
Study ID|MI|9fba0a8e-3fe2-4f06-b4cf-7aa401e971a7|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-07|39
Study ID|MI|1e40f81b-3d74-4582-9c8d-bd0f9c7a044d|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-05-02|196
Study ID|MI|eb393899-029c-4066-b337-87c4543b422d|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-05-20|285
Study ID|MI|2176468c-0dba-4e31-9fb0-2d8c58f0a96a|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-26|259
Study ID|MI|dfd17f44-0437-45de-9c6e-7cf4559269eb|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-26|267
Study ID|MI|b115ac47-1e2b-485b-8d75-936280817c9c|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-05-28|242
Study ID|MI|f2e017c3-9709-44a0-9fc9-6fb67695b97d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-24|259
Study ID|MI|322efb1f-10c2-41cf-8b4a-d84ae00b9faa|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-03|158
Study ID|MI|8c7d810e-4a9c-4df2-b1bd-585e3e0c29ee|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-03-27|167
Study ID|MI|6ea38426-aa83-4704-ab5d-2874505f731a|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-20|118
Study ID|MI|37741997-556e-4bb0-9a8b-dcba68aad5ef|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-07-01|296
Study ID|MI|3cc095a9-7201-4ee1-9d97-935fe761fb61|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-22|283
Study ID|MI|badb6da6-bea2-41f0-98fc-93ac3b8aed7c|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-07-12|263
Study ID|MI|ea87a2bd-903c-423d-ad46-3c53656bf49c|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-25|61
Study ID|MI|5f1ef0c5-2c53-43c1-8231-d68e65462800|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-02|262
Study ID|MI|39e8e130-6965-4eac-8eba-3e4af7aeea6b|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-11-27|84
Study ID|MI|b05aafad-12da-4c19-85aa-845cf6f6819b|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-07-11|291
Study ID|MI|0c7eb347-7a5a-4be1-804e-9a51d1690b28|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-14|191
Study ID|MI|f4eae613-6019-4f7f-b1db-223290b90a34|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-22|105
Study ID|MI|fd9d14f6-9c92-45db-b709-633924577209|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-06-19|294
Study ID|MI|3489f7bf-ab6e-4f96-a65b-f1748be4c4b8|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-15|211
Study ID|MI|11c7db3b-f41f-49c7-9b23-abc30f90bfad|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-12|214
Study ID|MI|b7a8e338-2d22-4b6d-b659-bb404a4501e0|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-29|99
Study ID|MI|8fe35032-c39c-4344-8f02-b9fd301a42bb|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-08-03|284
Study ID|MI|326c0467-89b9-4ca9-9869-45d895d9c833|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-29|251
Study ID|MI|1891448d-dbbd-4154-a793-0f7498187060|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-06|195
Study ID|MI|9eba0bdd-c6cb-4a39-b1c6-43af7281d383|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-10|167
Study ID|MI|018e26b8-610c-4ffc-ab50-d2abddadfbd3|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-08-16|294
Study ID|MI|d697be0b-c117-4262-8431-859e7641370b|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-24|112
Study ID|MI|1325428d-d272-4950-9588-27dac0f58b2d|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-14|78
Study ID|MI|090de1de-e936-4be2-a746-62fe121f7da8|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-05|162
Study ID|MI|51e2b6a9-dabf-425b-8263-88ec0bc326df|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-24|28
Study ID|MI|f6a7da73-f887-48fb-a8dd-dba1df8264ac|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-17|262
Study ID|MI|e4d806f1-76f0-49ca-8bbb-8c23827c4cdc|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-18|36
Study ID|MI|448187d1-4bec-472e-8cff-b945923aeb54|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-06|126
Study ID|MI|6b89a0c6-7ba2-49b1-b8b4-98ee72a8d610|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-01-30|111
Study ID|MI|48bd4478-8623-48a0-be65-6f1024caf526|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-06|227
Study ID|MI|4aa4833b-07b3-4f10-be23-98d8449b562c|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-18|17
Study ID|MI|bd0bf10f-4c49-457a-9d98-b7f007619beb|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-23|116
Study ID|MI|d0fbd021-74a2-4c6c-9a37-88b11e02e00a|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-12-03|35
Study ID|MI|70630273-d909-4fbf-b576-8dcb9788749e|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-09-22|39
Study ID|MI|a7330018-d906-4045-863f-cdeee9d0404c|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-20|125
Study ID|MI|28ef3051-2a9a-4935-8177-bb4ead0807f3|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-22|91
Study ID|MI|30f1e4f7-89e3-47e9-a6bf-c456f77ae0ae|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-12-14|46
Study ID|MI|b4a535cc-d816-4c2d-96af-08b3a11fd61f|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-23|124
Study ID|MI|94ee6fa6-c06a-424c-af88-76e7d8e4cf17|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-06|139
Study ID|MI|b38c5cd8-6c9b-4997-9657-261c705eb0f2|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-06|13
Study ID|MI|39def9d8-a452-486b-b1e8-12bebd4c36da|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-20|255
Study ID|MI|7d08a831-9e94-440e-828a-4ba3a85d5841|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-10|89
Study ID|MI|59795f52-5ee4-4a72-8b03-87e04bb0e87e|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-01-10|142
Study ID|MI|b1ebda49-a95a-4140-b833-154fe8ab3401|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-15|247
Study ID|MI|fa311f24-630a-411a-a48f-3c3b07e213d2|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-24|116
Study ID|MI|f12d0bcd-16ab-420a-ab4c-a8e688285fde|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-08-04|292
Study ID|MI|c307f13b-c7fe-437b-a990-e00f4e1f104a|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-24|220
Study ID|MI|6c12bd19-7c12-411e-ba09-c9a4dce7ffd8|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-09-25|30
Study ID|MI|eb822c77-ec30-4c17-bb12-bfb773c9d3eb|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-13|138
Study ID|MI|c13f95cc-1a44-4b19-a007-4e6db10f9d94|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-08|129
Study ID|MI|d0c75130-9899-4931-8ab5-ab5f0811f9c1|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-07-31|291
Study ID|MI|59bb2cf4-a255-40d4-9d73-6d1114e2b8a9|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-16|261
Study ID|MI|9aa5a461-1f6e-4dd2-bb06-e01d71ab3cce|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-07|237
Study ID|MI|ed9b7770-a013-48b1-bd83-3761f33c675f|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-26|69
Study ID|MI|30f82443-3ada-472b-b68c-281db036c5b7|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-19|122
Study ID|MI|572f79de-369d-40c4-9153-a1f25fbb7e8f|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-04|94
Study ID|MI|ff46289d-51d9-4fe8-9709-39509630591a|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-13|227
Study ID|MI|243f053d-22b2-4468-a717-af7f22b7be1a|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-19|225
Study ID|MI|b93fe287-2430-4c53-a385-fabbf6ece60a|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-09-04|17
Study ID|MI|303cbab3-0804-43b0-8a2a-97fef0d5272d|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-05-23|276
Study ID|MI|a2cd90d1-73b8-47f3-bf1e-6662f47b7ad8|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-29|225
Study ID|MI|9f0a9ed8-d47a-408a-9a60-ab92ee14317f|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-29|262
Study ID|MI|5b922ca1-bf69-45e3-b16f-180ab68cfc8f|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-06|226
Study ID|MI|164be186-dcce-4440-a795-1130b543f736|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-01-17|96
Study ID|MI|655c7821-7058-486b-96bd-e0cb4e00d6ca|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-11-22|43
Study ID|MI|a414ce50-a635-461a-a109-591cda1040ca|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-07-14|259
Study ID|MI|e137040f-31fe-4c36-9fa2-d5917539d11d|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-09|143
Study ID|MI|cb063824-7827-4ba8-860f-13ea6401bd33|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-21|203
Study ID|MI|e89dc34b-13f6-40d2-86d7-a46fef07d855|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-11-27|63
Study ID|MI|7737fac2-0749-41bc-8249-0388b2fd68ef|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-20|283
Study ID|MI|ed838820-1c2a-4cb2-b2d1-a15a67a591e7|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-06-13|278
Study ID|MI|0c6caab4-8a56-44dd-83dd-f100286b9e74|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-13|239
Study ID|MI|2cace3eb-a9ed-4b42-9acf-3083596a70e0|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-01-25|92
Study ID|MI|d3d357d9-0a5d-4ad3-8cb6-5976f71accb3|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-22|168
Study ID|MI|14e47c8e-f157-4202-b16f-563957d7c7ca|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-06|137
Study ID|MI|cb700cc0-92f5-4a8c-b5e5-64ba84d1b22d|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-29|142
Study ID|MI|86d62168-ed8f-4583-9710-02d5f265e4d8|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-09|219
Study ID|MI|8833f332-3d59-42b9-98cf-814501052dfd|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-30|253
Study ID|MI|1549db45-529f-4d67-8deb-c44e5770fa42|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-11-09|39
Study ID|MI|7001ef0f-72be-48a3-b427-56e8e43422cf|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-01-30|163
Study ID|MI|12c6ab37-bc49-4067-9009-1e122459c621|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-04-03|206
Study ID|MI|a5463071-7429-40f2-9e02-337ae889669d|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-27|140
Study ID|MI|24169321-2355-409b-b819-e3a808ed24e9|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-09-16|31
Study ID|MI|cdca79f6-2e7f-462f-9c1f-ab7b06fc1843|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-12-22|91
Study ID|MI|8d9c886d-707d-40e3-8588-c6910dda733a|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-08-02|288
Study ID|MI|cb2f7899-e727-42d2-804d-5a4a60216e27|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-05-05|212
Study ID|MI|683c148f-7062-45e5-8292-a819f788d4ef|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-01|81
Study ID|MI|0854edf0-d4c4-485b-a2a6-af120559f427|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-27|96
Study ID|MI|d15128a8-f001-460b-a13d-b84c534549a5|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-01-20|132
Study ID|MI|6db4143d-10c0-47c1-b285-0dce306a0332|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-12-13|86
Study ID|MI|19bc0794-e5de-41d3-b963-023119d05010|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-09|119
Study ID|MI|f8391173-3563-4fd2-aecc-bb1ecd64d577|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-09-25|20
Study ID|MI|d1e5d6d9-4f78-41e1-b469-6566418bc856|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-07-18|271
Study ID|MI|e0cfd275-64aa-4995-995a-fbc5b5a368b2|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-11|92
Study ID|MI|93a5bacb-f220-45be-9329-5c73363ed53b|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-19|179
Study ID|MI|d3f324e4-1ede-4f14-94d3-ffbbef10d646|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-12-30|76
Study ID|MI|e5da9056-0005-4e1b-be83-cbc3d12764e5|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-16|99
Study ID|MI|4845fb08-1d83-49e6-8ff9-653c3f3394f4|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-04-24|200
Study ID|MI|b355f502-2f42-4dbd-aeba-23c83cc82261|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-08-28|5
Study ID|MI|dbd8c5b1-6ac0-4a31-94b9-4073da7d09a2|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-10-12|31
Study ID|MI|a670e73c-6a53-4f32-af2a-4a951d4a8ebc|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-04|231
Study ID|MI|3f3bb1b8-f058-49be-a1c0-1599d5c6f61d|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-15|217
Study ID|MI|11662041-2a09-422e-bea9-2439b4ec197f|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-30|286
Study ID|MI|4844756a-975e-458c-906a-aa8810210a03|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-28|153
Study ID|MI|ac6bb1a4-5711-4732-ab1e-ab8c7bcad0ef|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-22|225
Study ID|MI|66d82444-1e96-4aa3-8a6f-213e1c91aff8|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-07-01|277
Study ID|MI|85e322c1-c83f-4a50-a8b9-567f45aace35|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-10|78
Study ID|MI|88f390b8-2e4a-4ec6-90c0-627fd2ea27f6|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-02-07|154
Study ID|MI|9313ccd0-1f71-479f-976b-ff5182bf3fe9|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-02-22|178
Study ID|MI|55e15a91-a192-44f5-b72f-d364eb6b8331|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-22|200
Study ID|MI|325b6c89-ae9e-4463-8690-8a7c2a625467|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-28|254
Study ID|MI|2e0e8646-d205-415b-8223-dd72aa5681ed|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-20|81
Study ID|MI|664740e0-4da9-43fd-af07-1ec459ac3120|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-06|117
Study ID|MI|e2bcd781-5145-401f-93a6-967394fa863d|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-09-29|28
Study ID|MI|e6abc3f9-be68-415a-8eb6-868f74c2f238|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-10-16|60
Study ID|MI|e977fe2e-6626-4c88-8a05-d37f88c10df4|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-08-11|293
Study ID|MI|c403ce49-1286-4be1-b906-8ec089e4fffe|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-10-08|16
Study ID|MI|7d519538-945d-49c6-be2d-a8b61f42b962|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-18|107
Study ID|MI|0a2112c2-242b-40c1-bfc1-1db362eee1d6|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-28|288
Study ID|MI|1323f04e-64a4-4fca-ad08-ce9f8877ad19|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-01|65
Study ID|MI|debd39bf-afd2-4181-8dba-15969de2e52e|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-12-31|81
Study ID|MI|fe53160f-1cf3-4e3d-86e9-f579dfe7c3e1|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-12-22|88
Study ID|MI|1a37144b-9674-456f-9921-1cbad458c388|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-01-11|83
Study ID|MI|ecb9c7f9-d76a-49fb-9ee9-087f7442349a|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-11-21|68
Study ID|MI|8c57e3bc-53d5-4804-91a6-ad9cdb66f82b|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-11-03|30
Study ID|MI|e5973012-f101-497e-97ac-31dca1010976|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-08-03|294
Study ID|MI|69d3fc98-8093-4347-8d58-e32d75b8821d|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-01-26|116
Study ID|MI|8bdbec73-69a4-48b9-8663-13ef32c9a40d|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-23|224
Study ID|MI|3e9d07b3-f91b-4c6c-a9c7-7b97fdb9b0d2|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-04|217
Study ID|MI|ef3d99d3-a644-4dd0-b0c6-8921899aa59e|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-31|237
Study ID|MI|6c70f183-90ac-436e-b1b4-6c9d23b2dbc4|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-14|127
Study ID|MI|85cf4495-2bfc-41e5-88f7-fccea156c124|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-30|237
Study ID|MI|1330d021-2954-4531-a684-80f55b5a9644|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-05-24|277
Study ID|MI|94f2f9da-dd24-4135-b61d-ee48c9dd801a|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-29|216
Study ID|MI|cefcf4a6-bda8-4f39-8429-ccfaf2b815f2|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-23|288
Study ID|MI|5fd47059-e6ae-4ae2-84df-d5d6b19de07c|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-20|224
Study ID|MI|2b7029f5-5da5-4b3c-8b1c-190226b13524|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-10|239
Study ID|MI|5d80cf62-78a8-44fc-81a9-044537f0436f|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-01|164
Study ID|MI|6a24825b-2ccc-4905-aad4-4bbaf7d3ffef|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-02|175
Study ID|MI|c68b6ff6-fba7-4e68-9e36-3242b1182910|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-09|53
Study ID|MI|8e4a02c9-3671-49aa-99d9-5ff4a86b707d|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-01|184
Study ID|MI|3e684a59-b5ac-4730-a2fe-13595dc2c8a6|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-18|237
Study ID|MI|e38a9fd6-aee5-48b0-a13a-864415fe9728|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-04-17|243
Study ID|MI|d751eafe-b68d-4494-9109-7f13e6b64234|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-07|213
Study ID|MI|bf7ed2f3-70c6-4686-8bff-27fb4fab8c29|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-06|58
Study ID|MI|b01188af-a822-4411-a34c-65922fa92047|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-01-22|133
Study ID|MI|9b873e9b-37fa-4e3e-9068-a2b87fea1604|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-06|210
Study ID|MI|0cf1fa7a-9450-41d2-8bad-790918f3ff0b|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-28|133
Study ID|MI|217a3159-2d8d-40f8-9593-4730883a5f94|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-26|103
Study ID|MI|0c713211-b021-4d3b-bca5-4a90d0731fa3|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-26|228
Study ID|MI|324b1ffb-952e-40ae-b9d5-de801b0dd515|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-02|27
Study ID|MI|229d8b75-df53-4cf4-b163-4338f51354ca|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-26|191
Study ID|MI|36814c94-db9d-487c-81aa-22c2bfe89fb6|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-10|231
Study ID|MI|99f42caa-8619-4864-b717-42594d2c1c4d|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-23|180
Study ID|MI|fc9a7c4b-b2df-42d5-bafb-909b518df602|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-22|129
Study ID|MI|b72d89cb-cbd0-4a2a-b2b6-73ab91370632|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-20|158
Study ID|MI|60991758-1054-4201-9716-4b24ae56beaf|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-06-01|296
Study ID|MI|3dbd06b5-5838-4494-ac8a-cad254dae8ae|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-05|173
Study ID|MI|85fd26a5-3a3f-4fb7-adc2-000a24ec595b|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-03|275
Study ID|MI|f6de105a-14b1-49d2-a1ef-273e4f0729b7|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-09-15|7
Study ID|MI|09e91029-8b43-4d2f-a4e3-632be587394f|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-17|251
Study ID|MI|5c00668d-44b0-4d1f-8da8-435da5b088f5|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-03|176
Study ID|MI|09add726-3b75-472e-b0c3-6006a15380f5|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-12-08|41
Study ID|MI|b51ef82f-586a-4ac9-a0d6-4f68875f3f82|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-23|154
Study ID|MI|7bd4f72b-7c16-48f2-bc05-25e91e874731|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-03|175
Study ID|MI|130f73ca-f82c-4811-a177-5f7b00d48419|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-11|125
Study ID|MI|c54c8670-10d9-4405-9540-ae64c6af702c|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-03|258
Study ID|MI|80a63cef-bcfc-4b49-80bc-7f6cf7e77a71|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-07|264
Study ID|MI|2873c83e-0c3d-40b5-98ed-521ad0559370|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-11-27|68
Study ID|MI|05988326-eade-4aba-bba3-1ae3a95cf672|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-19|122
Study ID|MI|a2c5ff67-5280-4949-b01e-b6e148bfdf16|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-26|181
Study ID|MI|58434e9b-ce78-4bb8-8c19-3edaffd41442|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-30|82
Study ID|MI|29e2110f-69f6-47e7-b412-f1490d15855e|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-25|142
Study ID|MI|60fcbb9e-b305-4e8f-8f51-ec65bccba7c0|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-14|31
Study ID|MI|d54966ca-f53b-4ebe-80eb-43184a62a26c|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-22|42
Study ID|MI|85e86c83-ac59-4eff-9919-bc373b99ec0a|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-01|202
Study ID|MI|c5c66bf5-c3d4-4970-9aa8-aede675abbd1|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-06-11|240
Study ID|MI|c8869166-757e-47e0-ab64-263a9d7656b6|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-16|185
Study ID|MI|f86d76f1-768e-4e57-89b6-7aedc9354f06|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-03|99
Study ID|MI|fce3efcc-0df4-45c3-8923-68a138d27d73|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-25|200
Study ID|MI|ee0af298-ceb4-4439-8668-328d7b1f0b6a|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-12|176
Study ID|MI|d06e8baf-1bbc-4d73-b527-34fd1b395292|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-03|115
Study ID|MI|74717162-82c4-4d83-a77e-4f3078e4a004|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-01-11|82
Study ID|MI|6f3b2913-194d-4844-80d5-70a3701f5cb8|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-19|92
Study ID|MI|3b6b4fd0-0730-4398-8f67-9d8cbd4e8465|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-05-22|278
Study ID|MI|c208988f-4212-4eb2-b348-24442f85af9b|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-07|223
Study ID|MI|3791a6ab-a874-4b57-9611-26d8eb585711|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-09-08|29
Study ID|MI|814f4185-6b93-45b3-a04f-bc65b47af956|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-30|90
Study ID|MI|91b47cdc-d93b-415e-ac54-482a23e15c6c|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-23|160
Study ID|MI|0a501dd0-6dca-47e4-9d7e-a773a9c5825c|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-04|198
Study ID|MI|e929ba72-b74d-4c71-82f9-da766e17fd6f|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-07|272
Study ID|MI|1f125b08-c7fb-4c6b-b64b-38ce4a50a74b|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-14|199
Study ID|MI|f7ff7030-27e7-4d60-b511-2c6c2bd9eb4f|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-03-20|210
Study ID|MI|3d436511-0dce-4437-b15b-932141264f50|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-31|271
Study ID|MI|a0b6b2a4-910a-4c3c-87b6-48ee38dfa2f7|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-21|186
Study ID|MI|eb0b2151-9ebc-44cb-8667-15fe2bfd4e46|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-02|127
Study ID|MI|ab4630d3-b303-4abf-b74a-944ec3fdae75|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-04|24
Study ID|MI|885d9228-b3dd-4c95-90be-6596c61a3b05|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-22|182
Study ID|MI|01c22518-040f-41f9-ac4e-622da72ea8bb|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-26|195
Study ID|MI|2a190ec9-08e6-4b07-ae4e-da7c896fb02d|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-05-13|263
Study ID|MI|a90c7293-d8b1-4555-8b71-29e5d9707635|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-12|216
Study ID|MI|2b963e8c-d7d4-4a5d-8371-3ea9273624bf|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-11|133
Study ID|MI|64fdccee-e171-44be-b8a6-2cd692ac2a5d|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-08-05|298
Study ID|MI|273f51b2-e379-40cd-9db2-6dc6b8e27d7c|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-09-03|26
Study ID|MI|d5581a4d-39c5-4632-82e5-ac43f43641e9|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-06|50
Study ID|MI|23e77b5d-4802-42d0-8dba-af4b45303337|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-17|163
Study ID|MI|316f549c-6079-4363-a85b-e1e253be2f93|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-10|162
Study ID|MI|a3abeeb6-eaf0-4eab-a899-30705e4d155a|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-03-07|161
Study ID|MI|e08079a2-3221-4294-8448-fd50f847079c|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-18|216
Study ID|MI|e19a993a-4c6c-4c81-8623-722d532297ca|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-01|236
Study ID|MI|e0936e84-299e-451f-b8fa-ae8b6f9f83dc|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-09-28|11
Study ID|MI|825caa22-c4b4-4d79-9ee7-86d8bb490e7a|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-01-08|134
Study ID|MI|8fe536c8-85cf-4f2a-87d4-05764a9bc9ec|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-14|60
Study ID|MI|1951f531-f305-4020-b2f5-1763a5caf825|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-11-17|62
Study ID|MI|530b8498-6e55-433d-b9b8-0e439fbc2a76|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-12-03|107
Study ID|MI|9e950611-579d-4c71-afff-2cd2d5dc37a5|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-02-21|168
Study ID|MI|b44bf72e-cf3c-43ff-a9c0-68a7115fc254|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-01-01|73
Study ID|MI|e1409bdb-3da1-43e3-bfd5-910e263b4451|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-06-23|266
Study ID|MI|c814d769-4ae9-4330-9aa3-27726bcf47b1|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-30|108
Study ID|MI|344de0e1-fade-42e7-a779-074a00dfafa0|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-04-11|236
Study ID|MI|91e53c15-99c3-40da-82f6-cd2ee96ecee6|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-11|198
Study ID|MI|cae377f3-e022-4abe-82a0-2ef6cb6c6b82|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-07-03|261
Study ID|MI|a945ed2b-40ca-4142-a6d8-6e14451d8a4e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-01-08|122
Study ID|MI|d18fdc52-3a8c-4c0c-8839-0dbd23663dc9|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-10-16|24
Study ID|MI|f97bb27a-15d6-4dea-b575-38574128e3e0|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-16|161
Study ID|MI|7842c627-54d1-4afb-b863-3ef84d7b335a|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-30|72
Study ID|MI|d1fe1ae9-17b7-40dc-8250-67515f6659b8|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-30|55
Study ID|MI|1f438f27-e049-4f32-b59d-2acda0e39316|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-04-08|172
Study ID|MI|20e1ef99-3101-4fc3-b6c6-f7b7d87f5585|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-09-15|18
Study ID|MI|030ef2b4-fbd8-4b11-a8af-8d16f2b16007|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-19|205
Study ID|MI|63336123-e50a-4ab9-b5e6-3cabc3743244|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-12-01|97
Study ID|MI|34a1462e-fa46-4fe0-bcf8-9aec157ecc7e|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-09-10|15
Study ID|MI|59ffc393-9862-4a7c-af96-c7c27375bc0c|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-10|77
Study ID|MI|2784bbb9-6f8b-450c-97ee-0f05afc7a497|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-01|216
Study ID|MI|e0f7f8f4-bc53-457a-b1e7-334d80be8ce5|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-10-14|34
Study ID|MI|2e012a0a-8b8d-4c4b-93bc-9c4856d84648|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-06-03|268
Study ID|MI|9c7788ce-b9c4-4410-8cd1-e3acb135fe30|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-09|187
Study ID|MI|08a80286-6add-4dce-bbe6-b82cc0acc896|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-27|72
Study ID|MI|6fbbc5b9-1a74-40d0-9448-41e909dd41a4|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-10|202
Study ID|MI|ad425a12-3cf4-4946-8f9b-daae4296fa21|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-10|109
Study ID|MI|bf793505-2348-407b-bcf6-813e5bcb71f3|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-23|185
Study ID|MI|b2fc787c-4951-4884-b680-e7c57416c68d|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-14|56
Study ID|MI|7587dc09-07b9-4d28-a07c-c173ee7f785f|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-10-05|54
Study ID|MI|9bfee219-aaa1-48c3-a971-5cb6fe2f930e|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-09-26|19
Study ID|MI|657a8fa7-8788-4993-bd8d-d2e86a4572b7|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-01-03|119
Study ID|MI|f25b0eae-0a80-472f-94b8-c5d4f35ea9ee|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-11-05|74
Study ID|MI|3b1ec433-5317-4320-a601-36e1c72db8c7|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-27|52
Study ID|MI|fbadb011-97b4-4423-bf72-8bb4774381e4|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-08|206
Study ID|MI|3ae6412f-08b1-4d32-97da-58e3176856b5|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-13|278
Study ID|MI|c11083b3-523d-451c-9e98-4f4738c45b7a|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-06-19|281
Study ID|MI|8c41ca81-05e8-42a1-86aa-fdf787ba5ba9|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-12-30|109
Study ID|MI|409a8a8f-13e0-4929-a97e-14daef23bef6|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-12|247
Study ID|MI|da4ebea3-ae83-4370-b62a-a96db1b12b94|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-23|64
Study ID|MI|cf675c93-71a6-4e6d-bb9e-4cb880f39d0c|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-05-13|270
Study ID|MI|2c2d051b-9dd9-4899-8ddb-b2f00f97c046|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-04-09|167
Study ID|MI|fcac6ec4-f62f-48ef-9f90-5342ea4bcd5c|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-11|146
Study ID|MI|4d8033a3-b04e-4f93-b644-75caca7d00bc|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-20|124
Study ID|MI|febce16b-a7bd-4d15-8686-5d9c021c8062|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-15|113
Study ID|MI|88704a8c-b2f9-4b83-ac37-be443121d27f|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-30|297
Study ID|MI|ef5270fe-24e3-4df8-9e0a-b64a033828fe|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-14|105
Study ID|MI|f9aa875f-6ddd-4fe9-80ca-e12ab3d12f45|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-04|84
Study ID|MI|ffe35386-c166-44f6-8fdb-f1feae2b078e|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-04|89
Study ID|MI|df12b0b6-0854-4fb9-8b90-f87021c31013|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-07-09|270
Study ID|MI|1baa76bc-cc44-42cf-9585-0fda2afe6740|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-25|221
Study ID|MI|46265849-9afc-4952-b01d-aa593948576f|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-18|28
Study ID|MI|ed5681ef-04ae-4c9c-8af0-998801808ec0|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-15|136
Study ID|MI|dc5e28e0-8e0f-4fea-9c63-170cb52a5514|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-07-11|275
Study ID|MI|eeb49ee5-dca4-49c0-bc17-899504023412|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-09-27|10
Study ID|MI|bdbcca7f-96e4-4ab3-a10c-433fb2f1b647|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-16|216
Study ID|MI|b9309a9f-6f69-4d99-aab1-aed10a722e77|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-20|72
Study ID|MI|3ca9e210-6f76-4881-b538-f8ce79ccfc57|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-04|81
Study ID|MI|2821bf2d-e4d8-483c-8f7d-37d44889728d|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-01|203
Study ID|MI|6d516ba5-96b3-4cfe-91a1-a350569866c6|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-01-26|89
Study ID|MI|c217b3ca-addb-4c12-95f2-b58583bedcd8|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-09-15|9
Study ID|MI|abb79778-ee30-4e6e-8da6-315ed44f1e86|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-25|27
Study ID|MI|9e2c3174-5021-49a6-86c1-4a95ca7ea2dc|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-02-12|160
Study ID|MI|8c1c8309-1e5d-4293-9657-3a1f4f1d4e4f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-01-27|117
Study ID|MI|c0e615c3-b9cb-469c-83e0-6e2e96b96e82|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-01-14|88
Study ID|MI|980b659c-8a12-4dd9-b589-f3492331fc70|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-09-27|50
Study ID|MI|c2f0ff14-ddad-46d2-a2cd-30ff2c6b6481|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-29|259
Study ID|MI|0c97f3b3-9c2c-40a9-b101-c692977ceaef|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-10|136
Study ID|MI|b02ce526-b4bb-49e3-ad64-7c3ccc43f4a5|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-04-29|191
Study ID|MI|44d7d97c-25b9-4c6b-991b-2fed8b476263|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-01|137
Study ID|MI|a81fca99-3517-4b04-ad22-6bfee2a1cc49|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-14|200
Study ID|MI|cf2dc23d-bb37-49c1-9cab-a1b06cbda411|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-14|61
Study ID|MI|8e034ca3-fc19-427a-82ff-f12581d19619|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-11-24|57
Study ID|MI|9a0f0a03-746a-49bc-8ef6-a2b206506aa1|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-04-19|235
Study ID|MI|2e11edef-2791-410b-8089-96bdfc9b73d7|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-15|116
Study ID|MI|d232c4af-8771-45b6-8727-a5a00e2085d4|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-07|17
Study ID|MI|4910eeaa-f945-4c7a-94ac-c7f1d9456ff8|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-07-06|253
Study ID|MI|eaf2a5bb-519b-4d63-be7c-a33be121f5c7|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-12|121
Study ID|MI|d131691d-6cc7-4fb9-92b8-e82d6c286389|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-27|81
Study ID|MI|a2284a75-da2f-4157-bcc3-8c19d8aa91a2|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-25|202
Study ID|MI|96690d2c-8ee6-4217-b728-4f3963e78c0f|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-28|70
Study ID|MI|dc2d731e-5302-4b55-a0fd-126cac25413e|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-01-07|101
Study ID|MI|baf33df4-7387-411e-8239-ecd5bc2aa3dc|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-27|155
Study ID|MI|7d45c9cd-ad39-4c9a-8dcc-bc6087e0cf98|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-07-10|264
Study ID|MI|f2742b1c-53d1-454b-ada5-bff2c2e7c755|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-03-21|204
Study ID|MI|d8208864-fa0f-471a-a822-8cb606703cc2|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-21|182
Study ID|MI|d4237095-7463-4f02-b85a-a073e859ddef|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-06-24|265
Study ID|MI|3e507d13-a5be-4959-8f44-d057ead8d683|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-12-16|125
Study ID|MI|15432e91-6157-450f-bb5c-024aeea0ea8a|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-02-10|121
Study ID|MI|773a540c-2192-4d70-b1f4-c87a425ca0f5|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-03|151
Study ID|MI|bfd02605-982e-4d42-8bbd-817e736cd501|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-26|153
Study ID|MI|6bb46b4f-3727-41d0-91cc-fb7b4540b3af|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-25|238
Study ID|MI|91250cab-9762-4c18-81b2-8d8d5fc8b193|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-01-25|115
Study ID|MI|d80c7117-562a-4233-add0-d216c6d8ae62|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-09-19|44
Study ID|MI|10b3ab23-8eea-409f-8b9a-22fc1a6b7e94|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-11-10|43
Study ID|MI|848dd063-1b33-4487-8aaa-01757cb77046|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-12-10|117
Study ID|MI|63a3bf0f-18a8-402b-bb40-d68bc96adc98|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-27|211
Study ID|MI|06a270fe-45b6-406f-a543-4cb7240ebad5|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-17|141
Study ID|MI|8ccf883c-fec1-41d8-87f4-3c8acea6dad4|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-09-30|27
Study ID|MI|c4cd72ee-a69e-4918-b4ee-749907a13b09|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-27|149
Study ID|MI|24d359a0-1b45-42df-bd8b-65856237b539|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-11-09|57
Study ID|MI|6cc10a89-4636-45dc-a2b5-4722fe7b4f70|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-07-16|294
Study ID|MI|136b774c-27d5-4513-ab9b-e359df78dc12|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-11|156
Study ID|MI|0cd176fd-cf7d-4be6-ba63-d4e363bf3b40|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-01-31|152
Study ID|MI|5fcad72b-cd2e-40ce-b2a4-f50768708c77|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-10-03|29
Study ID|MI|133aa3a3-b051-4faa-b737-1851d7935fee|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-01|117
Study ID|MI|a0293fb2-4ec2-48a8-be40-5936bc7cdde3|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-07-01|257
Study ID|MI|1e612989-bd41-43fe-82bd-18b651c6c5ca|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-14|56
Study ID|MI|91cbb9a1-c45e-471c-b09d-98de638b7a30|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-07|137
Study ID|MI|fb2835ae-39a6-48dd-93f4-006b40dc947d|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-11|50
Study ID|MI|fcc5702d-44d6-4ffc-b81c-b121c1b058a9|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-08|15
Study ID|MI|df209108-bad2-4312-a372-1ca91d659760|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-02-06|120
Study ID|MI|abca5aba-8fa2-4ecd-9416-42ea63ef1d63|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-21|205
Study ID|MI|32683fbe-91aa-4e78-9cba-b9f507008b73|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-13|101
Study ID|MI|118261a7-9740-4085-bfee-32fcdf7e2e73|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-05-18|265
Study ID|MI|af31738e-c84d-4a27-b641-01ebc124fea2|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-02-28|142
Study ID|MI|a92e4637-f1eb-4a92-8ebf-9cd094ac7e6e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-26|38
Study ID|MI|1347b170-a767-45a1-afd9-429d63fb750e|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-06|235
Study ID|MI|8ece4da9-30d6-4c7a-8ad1-09234b4004cb|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-07|10
Study ID|MI|5812af5b-fea6-408b-a4ec-5bcaf5664495|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-08|250
Study ID|MI|c87f8dfc-095a-41d3-8cc6-69ac5c214f45|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-20|191
Study ID|MI|fcecb8f0-b1c9-421f-b3e9-a29c4292ce89|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-21|69
Study ID|MI|5601d848-0311-4526-8522-4b3028a88651|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-11-30|94
Study ID|MI|cdcd8764-b9d7-4329-bf91-ea2571753b41|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-02-27|200
Study ID|MI|69b001c0-9041-4e54-bfb2-fcfae2f12293|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-07-27|293
Study ID|MI|4c9431ac-bd26-48a5-8303-86bf54f91e22|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-03|260
Study ID|MI|364dde94-41af-4b6f-b984-192ee3ad71e1|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-12|115
Study ID|MI|ddb801ce-53aa-4f8c-8ba1-c144c6c85d90|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-23|67
Study ID|MI|1a584105-d14a-4717-9454-e2c3820381f8|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-13|227
Study ID|MI|e43cdc5b-98d1-44d8-8d04-04711fad7f74|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-03|221
Study ID|MI|046e07bb-a83a-4162-ae06-6a99ebf1b89e|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-07|105
Study ID|MI|da8dfa1f-96a2-4d04-9d7d-3d38c38553fd|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-05-11|248
Study ID|MI|83875d10-6b8d-4ee7-b603-b8def51a7461|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-15|176
Study ID|MI|33e4bc92-e0fb-4067-bec6-91cb7a6a74f3|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-02-23|133
Study ID|MI|32af130e-ded7-42b0-80d2-ef2ab8cb3716|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-12-30|105
Study ID|MI|c5fb53bb-44b4-4b5c-b761-4162d98ebc17|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-06-01|274
Study ID|MI|2a1a2992-8396-4304-8a92-9cd66a7369a1|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-03-02|183
Study ID|MI|6ba2f713-f79c-4a47-bbd7-92621654749f|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-05-18|209
Study ID|MI|0eda1b06-4864-40c9-9c20-9c925e1f783f|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-01-24|136
Study ID|MI|03869e30-d967-4f76-9c9c-a36a7ac7d42a|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-04|220
Study ID|MI|ad5bfc99-cd61-4bea-8df0-2755b2245233|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-28|271
Study ID|MI|414d02ae-7812-4727-acb3-de9d06ea42b2|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-10|248
Study ID|MI|d0ae8848-985b-4359-9bd1-ea5be3ccc25b|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-03-05|176
Study ID|MI|b62294f9-8b23-4dec-90c8-a24950aa7d7a|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-06-19|272
Study ID|MI|f17d2239-8ee6-4877-8505-755188fd7d8e|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-18|270
Study ID|MI|a5012fe4-fb41-4745-9c68-35255d3fef81|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-14|51
Study ID|MI|30957f3e-2568-43f7-988b-d7e8b8567bef|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-28|46
Study ID|MI|6cff0c5a-e346-401c-b190-4357112f0917|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-04-05|223
Study ID|MI|e1a36c62-1c14-42a2-bb96-4ab3c8b2649b|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-16|86
Study ID|MI|10abfe98-d242-4549-8099-3c8d50bdbb31|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-31|144
Study ID|MI|b85fe6ec-d44e-431a-ae48-22631d3da657|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-12-16|59
Study ID|MI|5e715398-874e-49ab-b056-faad57de02ee|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-03|90
Study ID|MI|20d29b93-4a30-4914-811a-84386d3e4f2d|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-15|208
Study ID|MI|abf73edd-8476-43ac-8c86-b12ec46cc06f|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-12-30|82
Study ID|MI|ed9b9e4e-49a2-47bc-bccb-2ae541395917|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-05|102
Study ID|MI|14714bb0-b3c3-47c5-a26d-45a0c29a6b75|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-12|134
Study ID|MI|8d12b4a9-3b4f-4bf8-9e44-1306a8fd2daa|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-02|118
Study ID|MI|c8e04db6-28fa-4c0b-8611-8df28ec93013|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-03|82
Study ID|MI|0e35ed14-e076-48cb-9f90-d559a4052575|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-02|194
Study ID|MI|70433e05-ff36-402f-a3f4-b0427084c7d6|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-05|108
Study ID|MI|07889b4d-b5c0-4609-b934-984dca657ea9|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-01-01|100
Study ID|MI|89e46790-b0d5-4441-b36c-6a902e0cb5d5|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-01|45
Study ID|MI|f3658539-a9d4-43c3-aac3-80276a70dfd6|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-07-11|275
Study ID|MI|8d18e5f1-661a-4970-991b-6c80e12d2058|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-10-16|12
Study ID|MI|58aeb7ff-d7ed-4c85-a6a6-69dcb56398e2|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-12-22|104
Study ID|MI|232ddf92-f565-4f3e-9a4d-e114cea61631|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-24|121
Study ID|MI|5007d0c9-4a11-4731-a110-f1864faf6854|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-28|233
Study ID|MI|85b48279-6cdd-48c7-b7eb-bd6e595e0f8f|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-01-09|83
Study ID|MI|581601c0-37e2-4ccf-9d24-55c599e44d84|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-07-06|295
Study ID|MI|83f371a4-b017-4ccd-ae39-3ec0222a5ea2|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-01|122
Study ID|MI|eb29f19c-b1ea-4618-bae9-a361b44ff63d|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-10-30|19
Study ID|MI|6e271652-436d-49c6-b3a7-d66728d83df2|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-11-27|62
Study ID|MI|d604ff11-f208-4ed0-8aaa-d9f2e6801a80|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-11-14|32
Study ID|MI|49817fe6-5663-49b8-861e-79099a5c9798|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-08-14|296
Study ID|MI|f0f58cb2-e314-4869-b28f-a143a705a667|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-01-04|147
Study ID|MI|6b24c2d9-7aa1-4b21-b13b-11162e1bf375|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-10-31|55
Study ID|MI|5a60ad4c-9966-47d1-9418-9f9cb058d026|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-31|273
Study ID|MI|2f385096-51a8-4c83-8805-8bb8888a6b0e|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-10|147
Study ID|MI|549a4864-34d9-4852-b90a-a4676ba46189|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-01-10|88
Study ID|MI|ed891416-d5de-4985-9858-1ddeba0fb3de|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-07-18|284
Study ID|MI|c594a6bc-d680-4e20-aff5-88a5ba520340|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-07-01|257
Study ID|MI|89e24da4-3b14-4bb5-aad1-93988184ba42|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-03-29|222
Study ID|MI|f7662580-466d-4a62-bb12-7074c0b93927|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-03-05|147
Study ID|MI|7f931cc2-b6e7-4a31-a510-d7832b76b94a|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-05-06|226
Study ID|MI|768fd6ff-701e-4fde-82e9-432fff3bc729|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-03|228
Study ID|MI|cb48c1d0-24f7-4803-9a1a-d5a35e4b06cc|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-12|168
Study ID|MI|060ee7f9-a05e-48df-ae4b-6ac2b8aea91c|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-27|202
Study ID|MI|510a8ff9-0d06-412d-8de6-f88cf734d3f4|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-06-12|286
Study ID|MI|c930bfa0-66b8-490b-a9fb-c6d0d98c79a7|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-28|169
Study ID|MI|212370d6-958a-4f10-99fa-52a82dd9642f|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-06-23|259
Study ID|MI|5b4d1030-da3a-4935-bad9-66f7f06a9011|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-24|232
Study ID|MI|b57c8ca5-e2cf-43a9-945b-69356c428ea2|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-05|148
Study ID|MI|ae30d67b-08bc-434f-a478-217b2c337bf1|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-08|40
Study ID|MI|80e0a3ad-4614-45fa-b7da-4e3a75948dd8|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-11-20|75
Study ID|MI|d2d84e70-17a5-426b-9950-eeb8400f3799|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-10-28|74
Study ID|MI|ab29520f-676b-4f65-ac81-82304aef6428|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2021-10-23|76
Study ID|MI|a2dd2ef8-c42f-4e17-aa79-72a1fcf94596|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-12-09|104
Study ID|MI|6d740f8e-f7d4-40ec-b8d9-2ebbdcd7fb65|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-10-22|67
Study ID|MI|55eeb8e7-c997-4f21-aa9a-92cfe57d6ade|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-05-08|270
Study ID|MI|f02d68f6-149f-44f8-ae15-004b13f2447d|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-06|155
Study ID|MI|0dc1253a-6f7b-4fb2-a008-832188c2baaf|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-06|195
Study ID|MI|4335a7d8-78a7-43a5-891c-b9db8066e4b7|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-27|59
Study ID|MI|34336761-a918-4570-bbb9-46fcf39cb60f|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-02-22|186
Study ID|MI|9b20980a-c8fe-4d09-aa6c-2022eeeafdc1|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-05-03|268
Study ID|MI|b8f38aeb-6f0c-42a9-b7ef-d054e379a0e2|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-07|25
Study ID|MI|2288a9c2-c5cb-4517-91a9-6f329b6c074c|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-07-07|292
Study ID|MI|a10ca8a1-71ac-4648-966c-a4fbe0ea9f6a|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-06-04|251
Study ID|MI|10173319-d6ab-4249-a3a5-4e60f68cf5db|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-02|163
Study ID|MI|9a049fca-bafc-4153-83b4-4dc70c68304c|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-09-01|21
Study ID|MI|285df392-2e9c-494e-852f-54950a3dad0f|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-08-05|299
Study ID|MI|b9c37acb-5ca8-40fd-8602-d0ad4482f2eb|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2021-11-19|42
Study ID|MI|e7ce576e-012e-4632-ada0-59e2a592d408|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-06-14|276
Study ID|MI|d8a4a180-a82d-4ddb-9274-5d83c70112a3|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-04-26|231
Study ID|MI|63706db7-5cac-4126-a1ab-dca325988bf6|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-07|132
Study ID|MI|9eed1701-6dbc-45c7-8ea7-4d5b686fb6ff|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-11|145
Study ID|MI|74d84f4c-4566-4249-96a1-533de932dd89|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-07-07|263
Study ID|MI|fe2e55ec-2e4c-4baa-9c92-60e7ed17c458|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-10-20|63
Study ID|MI|86bb2bc8-a4ec-4965-af26-11f4979f99bb|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-12|208
Study ID|MI|974ff09c-caf2-414a-ba3a-9b9471fbd620|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-05|129
Study ID|MI|c9ec4c3f-144a-44b6-b5a8-83bb25599c0e|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2021-09-21|41
Study ID|MI|713e69bd-2de6-434b-94ba-20b55da40e62|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-02-16|189
Study ID|MI|7ab6fabe-0ef9-4661-9eec-f16834285435|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-19|221
Study ID|MI|2d16c162-8f9f-4753-a06f-406c60f8bd9a|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-05|140
Study ID|MI|4fc2b201-daad-42fb-b99c-63629135b9ce|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-17|213
Study ID|MI|aaac8972-4d1a-45b2-ae50-57b398adf837|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-11-10|46
Study ID|MI|5921f5c3-9900-4dba-a835-77dfc8c43637|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-04-23|193
Study ID|MI|d4377c02-9a8e-4aca-a5b2-2669c963918c|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-05-05|241
Study ID|MI|d84da97a-bd8d-4dba-8eb2-e545c8eac4e4|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-04-25|199
Study ID|MI|9fc55af3-7317-40ed-bc56-1a89dd399808|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-04-21|211
Study ID|MI|a68f4255-fc70-4b26-a0c0-d6de9b7369d0|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-02-16|110
Study ID|MI|deae6b40-62c1-4064-bf0f-ab4f8fb92555|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2021-10-09|34
Study ID|MI|a564a6ed-ebde-4d1d-a934-b54eb473a48f|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-10-27|7
Study ID|MI|326438a0-7ab6-48c3-95d7-43bf8f86b14c|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-06-01|290
Study ID|MI|85d8f88d-a898-4915-a9c3-caa158d0b213|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-01|197
Study ID|MI|2d55e323-8719-4ffa-ab70-11adf033ce07|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-04-01|157
Study ID|MI|0246f358-ce63-4bd6-a125-594ff357723e|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-03-16|164
Study ID|MI|149e623e-b430-45e2-924e-46c437f3db59|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-02-17|163
Study ID|MI|fcb09a08-0491-4bc4-a9b1-1fbd89586f71|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-23|212
Study ID|MI|b5ad47f0-2842-430f-a0d9-aba11223ccfe|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-06-11|272
Study ID|MI|1075bd3e-efcb-419d-8725-fab6f0c13f3a|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-10-14|53
Study ID|MI|55a344d4-09b0-470b-9607-a19be9d5bd8d|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-10-19|3
Study ID|MI|4fa27209-acde-4b73-852c-9124a6608f5a|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-07|167
Study ID|MI|d692395a-1a30-4960-95f6-7e854c9f7ce4|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-01-08|110
Study ID|MI|ac690278-07ba-4f47-ad36-f90640c4cac1|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-30|279
Study ID|MI|3344cb70-4cee-4871-9e3c-ee86dc8c09b4|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-07-12|256
Study ID|MI|0ed45504-ee29-4f01-9777-b71461c3f915|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-11-29|85
Study ID|MI|9d5ab0d2-0ca8-4747-b374-5bc2ec812b53|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-03-05|168
Study ID|MI|1dc9438c-e39c-4aa6-8d08-3702919ebe2e|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-03-29|213
Study ID|MI|9492e29a-7a6a-46f2-aa3f-c751b4c2f77b|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-01-26|96
Study ID|MI|82c7c099-b23e-4658-aca5-f51872352237|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-11-04|69
Study ID|MI|3c34e10b-33bf-4e47-b2c6-4beaa9855655|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-06-17|263
Study ID|MI|8bb18393-9df8-4a39-8fcd-46c740b3b0f2|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-11-13|52
Study ID|MI|c332cb21-29a0-40a7-903a-cfc7e924cd3e|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-26|246
Study ID|MI|12e20b79-d475-45d0-913b-692c4bd6b77c|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-20|25
Study ID|MI|47ae4992-d9f2-41b8-b2bb-57b79f4d86a5|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-05|163
Study ID|MI|b6f61fd5-1cae-4def-8da2-1155777dace4|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-11-03|30
Study ID|MI|bf1aba67-4c57-4e5b-9c56-bad135c55428|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-09|79
Study ID|MI|821b34a1-4785-41de-9af0-cd213b51f70e|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-10-12|12
Study ID|MI|de9a8eef-40d1-46d0-ad17-0139e1ef6da7|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-08|140
Study ID|MI|ebbee535-ce64-49fd-89ca-81b022838a8a|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-17|111
Study ID|MI|86577261-79c9-40a0-90f6-341cc56dd879|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-30|85
Study ID|MI|1af42d8c-ea33-447a-bc0e-7a5aef9f58a0|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-01-05|84
Study ID|MI|59e4a43c-093a-47ec-af14-f59735ccce87|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-03-06|158
Study ID|MI|5cb7a6b6-7e48-415c-a616-3db61858a2b9|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-06-25|266
Study ID|MI|f3c49594-5c9e-4c45-9e0b-5c07b0f71596|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-08-25|3
Study ID|MI|566b7b8c-95bf-43c8-b71f-4e3fab6d3fbe|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-08|42
Study ID|MI|6e7b3388-f0fe-4867-9037-202cab925b1d|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-03-08|143
Study ID|MI|1e595d68-b74a-499e-801b-5f6a708e39c3|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-09|119
Study ID|MI|0dd22462-a34b-42ab-ad3d-2b4c029b9399|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-06-12|264
Study ID|MI|e653c9e9-26ff-4b4e-80f1-464dc0995a42|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-05-24|282
Study ID|MI|a3a8b4fb-1d7c-444f-9011-d037bfdec8a7|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-10-19|69
Study ID|MI|379863fa-bfee-4e4d-befe-b8fd41c364ff|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-01|37
Study ID|MI|b06186b7-1214-430a-bab2-df8236efd19f|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-10|59
Study ID|MI|55195f1a-0df1-40b2-8c58-835ade2af55f|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-09-20|29
Study ID|MI|eb79afb1-9c3a-454f-baa5-627758587ac7|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-11-28|52
Study ID|MI|781798a9-20dd-4cc9-bb23-5794f2eb7336|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-04-09|169
Study ID|MI|ade91982-0b4d-4d0d-b21f-d3abf6dc96f5|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-24|199
Study ID|MI|00e59aa5-5211-459e-ac38-bbafb5ff3f24|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-07-02|294
Study ID|MI|e99cb8c0-6dea-446a-b798-9c83a8d7e7a5|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2022-02-26|160
Study ID|MI|58b27f5f-433c-4663-99f8-b05eaadebcf1|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2021-11-15|101
Study ID|MI|05ad2b06-dee9-46de-bd5a-82370ab7619e|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2021-12-19|116
Study ID|MI|fae01538-e100-4d2c-98ef-c3713d1d7081|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-05|77
Study ID|MI|a510ec7d-0345-4e62-b40c-80c8cfa7cd20|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-08-14|2
Study ID|MI|fea49005-0bfc-484e-98e6-ac47d64fbf56|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2022-07-03|272
Study ID|MI|b2c1c740-dabb-4c35-9ec3-89fa8b631104|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-17|146
Study ID|MI|66ae8b7c-4307-4873-8dc0-37d451513ade|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-01|112
Study ID|MI|4f522ceb-0594-4d09-a8dc-ae62fc25b236|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2021-10-17|27
Study ID|MI|38cc70be-90f8-4047-a6c3-202950fd7bf5|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2021-12-27|70
Study ID|MI|19f9dd2b-c46c-4629-94dd-d38b92434e2b|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-21|171
Study ID|MI|2edbba86-21c3-4d85-a985-b3a6916f9f97|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-02-04|117
Study ID|MI|44914c1c-b117-4162-8da2-c1689a94b998|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-04-20|256
Study ID|MI|e8e27076-473e-4293-b243-1bb94b3bf269|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-07|80
Study ID|MI|cd33ac34-c57a-49c6-b847-59effff0d1c4|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-05-11|258
Study ID|MI|2d6d1b14-f011-4f9c-810e-ea30fb92a74f|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-11-17|67
Study ID|MI|d22fb880-8b73-4eee-8f7d-7ef0eecd8bd9|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-03-13|136
Study ID|MI|09ee7713-76e0-4c7e-9b09-ed1e30338692|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-07-28|297
Study ID|MI|4ba85b15-78bc-4434-9473-b728a29918e7|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-02-15|121
Study ID|MI|ae3512e5-96ff-4ed1-8756-b279cb283132|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-11-23|26
Study ID|MI|f6e6bd11-b4ef-4eb5-a21e-9a5406abb936|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-06-25|292
Study ID|MI|59ed4050-4faa-4336-92bb-949fecdc4b00|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-04-24|195
Study ID|MI|3c2d3684-0d5a-4808-be0c-0823d8cb9df8|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-02-06|116
Study ID|MI|af4a272e-d496-4495-aeb3-385d991445cb|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-03-31|231
Study ID|MI|3f08021d-f0ce-4ec8-8391-230f3f955f51|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-12-11|46
Study ID|MI|a2e4b861-b070-4901-83c5-b00c4fd48d89|1|[?]|[?]|[?]|1|MALIGNANT|1|3|WASHOUT|2021-12-06|119
Study ID|MI|0bbfbb9e-0acc-45c5-a49e-6172d899c8d7|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-03-16|166
Study ID|MI|bd118e24-0744-4d61-8d3b-e39c8925765d|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-03-07|191
Study ID|MI|90402180-9860-48b5-b39f-2853f61f798c|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-28|293
Study ID|MI|a12d498c-5df4-49e4-9344-81dc0e85ae95|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-03-05|211
Study ID|MI|02653a1e-e5bc-424d-8d16-878d950e6477|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-02-12|109
Study ID|MI|1d2862be-1311-4934-8e2a-667a6b588468|1|[?]|[?]|[?]|1|BENIGN|1|1|SCREENING|2022-06-19|259
Study ID|MI|703313f4-61d3-41fe-acc9-c1167076306b|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2021-10-06|46
Study ID|MI|9e662145-d0f9-4b10-acd0-8084041a5101|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-03-07|154
Study ID|MI|5e99b934-db09-4b04-a001-8bcfd63b161e|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-09-09|6
Study ID|MI|48356313-8821-4814-b386-1426007dc54c|1|[?]|[?]|[?]|1|MALIGNANT|1|2|TREATMENT|2022-06-28|299
Study ID|MI|be84317a-930c-4f7c-bd68-c5a321eaabb0|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-04|211
Study ID|MI|c42b2179-384c-43f6-a5c2-8cb461303738|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-02-24|155
Study ID|MI|686be7c0-f49b-44ba-ba30-d1d9c00d0f4e|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2021-09-11|35
Study ID|MI|8cb48d4c-1f19-4d4d-8604-8116b52e6ced|1|[?]|[?]|[?]|1|MALIGNANT|1|4|TREATMENT|2022-03-09|197
Study ID|MI|a0123519-cc0c-4792-9644-b586d66cbee3|1|[?]|[?]|[?]|1|MALIGNANT|1|5|WASHOUT|2021-10-23|67
Study ID|MI|5a318a1f-73aa-426d-a74f-51d34974bbdf|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-05-02|207
Study ID|MI|fb6cd756-1ebc-46e5-9bf5-72190d6f9e5c|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-06-21|249
Study ID|MI|251a673b-c882-4808-a1e0-37a01262b58a|1|[?]|[?]|[?]|1|BENIGN|1|6|TREATMENT|2022-04-18|251
Study ID|MI|81479285-f19f-44b5-96c3-a23c08894e21|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2022-06-02|233
Study ID|MI|8b72db84-3214-4393-9344-7b01ffd75a8f|1|[?]|[?]|[?]|1|BENIGN|1|3|WASHOUT|2022-01-13|101
Study ID|MI|e137fe71-a123-4b88-a1b6-b49f510bebeb|1|[?]|[?]|[?]|1|BENIGN|1|5|WASHOUT|2022-06-18|245
Study ID|MI|84980f4f-a492-4502-9779-5f0eb0a4c6a2|1|[?]|[?]|[?]|1|MALIGNANT|1|7|FOLLOW-UP|2021-10-22|33
Study ID|MI|602009f9-f365-4d39-a286-e781386731c8|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2022-02-13|125
Study ID|MI|b2c2afea-6336-4b56-80e0-1d22ac07de48|1|[?]|[?]|[?]|1|BENIGN|1|2|TREATMENT|2022-01-03|66
Study ID|MI|1044cde5-b270-498a-9e54-af607177b34c|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-03-27|157
Study ID|MI|02eb41cd-6bea-4a56-b021-a3a8bb3930ca|1|[?]|[?]|[?]|1|MALIGNANT|1|1|SCREENING|2022-05-23|217
Study ID|MI|4913919b-0dc2-4fc1-a7ca-f282ce7249d3|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-05-03|188
Study ID|MI|736c3d8e-42f5-4c39-89ef-42a7883f33c1|1|[?]|[?]|[?]|1|BENIGN|1|7|FOLLOW-UP|2021-11-07|53
Study ID|MI|9847eca9-c477-4a03-96ab-3ad77da580bf|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-04-12|194
Study ID|MI|652a6c34-caae-455c-939b-de93c811b8e4|1|[?]|[?]|[?]|1|MALIGNANT|1|6|TREATMENT|2022-08-03|278
Study ID|MI|7265965a-9dee-479e-91ff-99e4b3d38be5|1|[?]|[?]|[?]|1|BENIGN|1|4|TREATMENT|2022-05-10|202
